

1 **Title: A distinct cross-reactive autoimmune response in multisystem**
2 **inflammatory syndrome in children (MIS-C)**

3
4 **Authors:** Aaron Bodansky¹, Joseph J. Sabatino, Jr.^{2,3}, Sara E. Vazquez⁴, Janet Chou^{5,6}, Tanya
5 Novak^{7,8}, Kristin L. Moffitt^{6,9}, Haleigh S. Miller^{4,10}, Andrew F. Kung^{4,10}, Elze Rackaityte⁴, Colin
6 R. Zamecnik^{2,3}, Jayant V. Rajan⁴, Hannah Kortbawi^{4,11}, Caleigh Mandel-Brehm⁴, Anthea
7 Mitchell¹², Chung-Yu Wang¹², Aditi Saxena¹², Kelsey Zorn⁴, David J.L. Yu¹³, James Asaki¹⁴,
8 John V. Pluvinaige³, Michael R. Wilson^{2,3}; Laura L. Loftis¹⁵, Charlotte V. Hobbs¹⁶, Keiko M.
9 Tarquinio¹⁷, Michele Kong¹⁸, Julie C. Fitzgerald¹⁹, Paula S. Espinal²⁰, Tracie C. Walker²¹,
10 Stephanie P. Schwartz²¹, Hillary Crandall²², Katherine Irby²³, Mary Allen Staat²⁴, Courtney M.
11 Rowan²⁵, Jennifer E. Schuster²⁶, Natasha B. Halasa²⁷, Shira J. Gertz²⁸, Elizabeth H. Mack²⁹,
12 Aline B. Maddux³⁰, Natalie Z. Cvijanovich³¹, Matt S. Zinter¹, Laura D. Zambrano³², Angela P.
13 Campbell³², Adrienne G. Randolph^{6,7,8,†}, Mark S. Anderson^{13,†*}, Joseph L. DeRisi^{12,†*}; and the
14 Overcoming COVID-19 Network Study Group Investigators³³

15 **Affiliations:**

16 ¹ Department of Pediatrics, Division of Critical Care, University of California San Francisco,
17 San Francisco, CA

18 ² Weill Institute for Neurosciences, University of California San Francisco; San Francisco,
19 CA

20 ³ Department of Neurology, University of California San Francisco; San Francisco, CA

21 ⁴ Department of Biochemistry and Biophysics, University of California San Francisco, San
22 Francisco, CA

23 ⁵ Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston,
24 MA

25 ⁶ Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston,
26 MA

27 ⁷ Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's
28 Hospital, Boston, MA

29 ⁸ Department of Anesthesia, Harvard Medical School, Boston, MA.

30 ⁹ Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA

31 ¹⁰ Biological and Medical Informatics Program, University of California San Francisco, San
32 Francisco, CA USA

33 ¹¹ Medical Scientist Training Program, University of California San Francisco, San
34 Francisco, CA

35 ¹² Chan-Zuckerberg Biohub, San Francisco, CA

36 ¹³ Diabetes Center, School of Medicine, University of California San Francisco, San
37 Francisco, CA.

38 ¹⁴ Biomedical Sciences Program, University of California San Francisco, San Francisco, CA.

39 ¹⁵ Division of Critical Care Medicine, Department of Pediatrics, Baylor College of Medicine,
40 Houston, TX.

41 ¹⁶ Department of Pediatrics, Division of Infectious Diseases, Department of Cell and
42 Molecular Biology, University of Mississippi Medical Center, Jackson, MS.

43 ¹⁷ Division of Critical Care Medicine, Department of Pediatrics, Emory University School of
44 Medicine, Children's Healthcare of Atlanta, Atlanta, GA

45 ¹⁸ Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of
46 Alabama at Birmingham, Birmingham, AL

47 ¹⁹ Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia,
48 University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA.

49 ²⁰ Personalized Medicine and Health Outcomes Research, Nicklaus Children's Hospital,
50 Miami, FL

51 ²¹ Department of Pediatrics, University of North Carolina at Chapel Hill Children's Hospital,
52 Chapel Hill, NC.

53 ²² Division of Pediatric Critical Care, Department of Pediatrics, University of Utah, Primary
54 Children's Hospital, Salt Lake City, UT

55 ²³ Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Children's Hospital,
56 Little Rock, AR

57 ²⁴ Department of Pediatrics, University of Cincinnati, Division of Infectious Diseases,
58 Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

59 ²⁵ Division of Pediatric Critical Care Medicine, Department of Pediatrics, Indiana University
60 School of Medicine, Riley Hospital for Children, Indianapolis, IN.

61 ²⁶ Division of Pediatric Infectious Diseases, Department of Pediatrics, Children's Mercy
62 Kansas City, Kansas City, MO.

63 ²⁷ Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University
64 Medical Center, Nashville, TN

65 ²⁸ Division of Pediatric Critical Care, Department of Pediatrics, Cooperman Barnabas
66 Medical Center, Livingston, NJ

67 ²⁹ Division of Pediatric Critical Care Medicine, Medical University of South Carolina,
68 Charleston, SC

69 ³⁰ Department of Pediatrics, Section of Critical Care Medicine, University of Colorado
70 School of Medicine and Children's Hospital Colorado, Aurora, CO

71 ³¹ Division of Critical Care Medicine, UCSF Benioff Children's Hospital Oakland, CA

72 ³² COVID-19 Response Team and Coronavirus and Other Respiratory Viruses Division,
73 Centers for Disease Control and Prevention, Atlanta, GA.

74 ³³ Overcoming COVID-19 Network Study Group Investigators: full list of the authors and
75 affiliations at the end of the main manuscript.

76 *Corresponding authors. Email: mark.anderson@ucsf.edu and joe@derisilab.ucsf.edu

77 † These authors contributed equally to this work

78

79 **Abstract:** Multisystem inflammatory syndrome in children (MIS-C) is a severe, post-infectious
80 sequela of SARS-CoV-2 infection, yet the pathophysiological mechanism connecting the
81 infection to the broad inflammatory syndrome remains unknown. Here we leveraged a large set
82 of MIS-C patient samples (n=199) to identify a distinct set of host proteins that are differentially
83 targeted by patient autoantibodies relative to matched controls. We identified an autoreactive
84 epitope within SNX8, a protein expressed primarily in immune cells which regulates an antiviral
85 pathway associated with MIS-C pathogenesis. In parallel, we also probed the SARS-CoV-2
86 proteome-wide MIS-C patient antibody response and found it to be differentially reactive to a
87 distinct domain of the SARS-CoV-2 nucleocapsid (N) protein relative to controls. This viral N
88 region and the mapped SNX8 epitope bear remarkable biochemical similarity. Furthermore, we
89 find that many children with anti-SNX8 autoantibodies also have T-cells cross-reactive to both
90 SNX8 and this distinct domain of the SARS-CoV-2 N protein. Together, these findings suggest
91 that MIS-C patients develop a distinct immune response against the SARS-CoV-2 N protein that
92 is associated with cross reactivity to the self-protein SNX8, demonstrating a link from the
93 infection to the inflammatory syndrome.

94 **Introduction:**

95 Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to a
96 broad spectrum of disease (1–3). The course of disease in children is often mild (4–6) but can
97 become severe due to a variety of known (7, 8) and yet-to-be discovered factors. In rare cases
98 children develop multisystem inflammatory syndrome in children (MIS-C), a post-infectious
99 complication which often results in critical illness (9–11). The disease was hypothesized to be
100 related to Kawasaki Disease, which presents similarly with prolonged fever, systemic
101 inflammation, rash, conjunctivitis, and can be complicated by myocarditis and coronary artery
102 aneurysms. In contrast to Kawasaki Disease, however, MIS-C is temporally associated after a
103 SARS-CoV-2 infection, and more commonly includes shock, cardiac dysfunction, and multi-
104 organ system involvement including gastrointestinal symptoms and hematologic findings, such
105 as thrombocytopenia and lymphopenia (13–17). Through extensive characterization, MIS-C has
106 been shown to have a distinctive inflammatory and cytokine signature, with evidence of altered
107 innate and adaptive immunity as well as autoimmunity(17–23).

108
109 While the pathophysiological link between SARS-CoV-2 and MIS-C remains enigmatic, other
110 autoimmune diseases are the consequence of exposure to novel antigens in the form of a virus or
111 oncoprotein. For example, multiple sclerosis is associated with Epstein-Barr-Virus infection, and
112 recent data suggests that B-cells and T-cells which are cross-reactive between a viral protein
113 (EBNA1) and several host proteins may contribute to disease development(24–26). In addition,
114 decades of paraneoplastic autoimmune encephalitis research, including anti-Hu, anti-Yo, anti-
115 kelch-like protein 11, and many others, highlight the importance of autoreactive B-cells and T-
116 cells working in concert to cause disease by targeting a shared intracellular antigen, and in
117 certain cases a shared epitope (28–35).

118
119 Though cross-reactivity has not yet been identified in MIS-C, multiple autoantibodies have been
120 reported (20–22), including those targeting interleukin-1 receptor antagonist (IL-1Ra) (35).
121 Distinctive T-cell signatures have also been reported in MIS-C, including an expansion of
122 TRVB11-2 T-cells(23, 36–39) accompanied by autoimmune-associated B-cell expansions(21).
123 Because the T-cell expansion is not monoclonal, many have speculated that a yet-to-be-identified
124 superantigen is responsible. However, recent experiments suggest the expansion may instead be
125 the result of activated tissue-resident T-cells(41), though the antigenic target of these T-cells
126 remains unknown. Altered innate immune function has also been implicated in a subset of MIS-
127 C cases, including inborn errors of immunity involving regulation of the mitochondrial antiviral-
128 signaling (MAVS) protein pathway (41).

129
130 Here, children previously infected with SARS-CoV-2- with (n=199) and without (n=45) MIS-C
131 were enrolled and comprehensively profiled for autoreactive antibodies as well as those targeting
132 SARS-CoV-2. Differential autoreactivity highlighted an epitope motif which is shared by the
133 viral N protein and the human SNX8 protein. SNX8 is expressed by immune cells across
134 multiple tissues and modulates MAVS activity(43). This cross-reactive epitope motif is targeted
135 by both B-cells and T-cells, suggesting that a subset of MIS-C may be triggered by molecular
136 mimicry.

137 **Results**

138 *MIS-C patients harbor a distinct set of autoreactivities*

139 To explore the hypothesis that MIS-C is driven by an autoreactive process, the spectrum of
 140 autoantibody specificities present in children with MIS-C (n=199) and children who had
 141 asymptomatic or mild SARS-CoV-2 infection without MIS-C (within at least 5 weeks of
 142 enrollment) (n=45, hereafter referred to as “at-risk controls”) was captured using phage
 143 immunoprecipitation and sequencing (PhIP-Seq)(44). The PhIP-Seq technique has been
 144 extensively used to identify novel autoantigens in a wide range of diseases, and the specific
 145 768,000 element human proteome-wide library used in these experiments has been used to define
 146 novel autoimmune syndromes and markers of disease for a variety of conditions (29, 33, 44–46).
 147 Given the inherently heterogeneous nature of antibody repertoires among individuals, the
 148 identification of disease-associated autoreactive antigens requires the use of large numbers of
 149 cases and controls (45). To minimize spurious hits, this study contains 199 MIS-C cases and 45
 150 at-risk controls with recent SARS-CoV-2 infection, which represents substantially more MIS-C
 151 cases and controls than previously published (Figure 1A)(20–22, 44). Clinical characteristics of
 152 this cohort are described in Table 1.

153
 154

Table 1: Clinical characteristics of MIS-C and at-risk control cohorts.

	MIS-C	Control
Number	199	45
Male sex (%)	118 (59.3)	24 (53.3)
Median age in years (median, IQR)	10.9 (7.5 – 14.7)	5.5 (2.2 – 11.1)
Race and ethnicity (%)		
White, non-Hispanic	63 (31.7)	14 (31.1)
Black, non-Hispanic	74 (37.2)	5 (11.1)
Hispanic or Latino	47 (23.6)	15 (33.3)
Other race, non-Hispanic	8 (4.0)	2 (4.4)
Unknown	7 (3.5)	9 (20.0)
Underlying conditions (%)		
None	134 (67.3)	36 (80)
Obesity*	29 (15.2)	8 (21.6)
Asthma	22 (11.1)	1 (2.2)
Cardiovascular	4 (2.0)	0 (0.0)
Immunocompromise	0 (0.0)	0 (0.0)
Autoimmune condition	1 (0.5) †	0 (0.0)
Malignancy	1 (0.5)	0 (0.0)
Hospital Course (%)		
ICU admission	170 (85.4)	0 (0.0)
Shock requiring vasopressors	90 (45.2)	0 (0.0)
Mechanical ventilation	38 (19.1)	0 (0.0)
Extracorporeal membrane oxygenation (ECMO)	8 (4.0)	0 (0.0)

155 *Does not include n=8 MIS-C patients and n=11 controls under 2 years of age.

156 †Patient on chronic systemic steroids for eosinophilic esophagitis

157 For any given set of samples, PhIP-Seq has the potential to yield dozens to many thousands of
158 differential enrichments of phage-displayed peptides. Here, logistic regression machine learning
159 was used to first assess in an unbiased manner whether there existed a set of differentially
160 enriched peptides that classify whether a sample is from an MIS-C patient or an at-risk control.
161 This approach has been previously used with PhIP-Seq data to accurately classify Autoimmune
162 Polyglandular Syndrome Type 1 (APS1) cases from controls (45). In this experiment, model
163 input included the enrichments for all recovered peptide sequences derived from each sample.
164 The training and classification were iterated 1,000 times using 5-fold cross validation, whereby
165 80% of the dataset is randomly chosen for training with the remaining 20% withheld for testing
166 the classifier. Examination of the largest logistic regression coefficients associated with MIS-C
167 disease revealed significant contributions to the classifier from peptides derived from the ERFL
168 (ETS repressor factor like), SNX8 (Sorting nexin 8), and KDELR1 (KDEL endoplasmic
169 reticulum protein retention receptor 1) coding sequences, followed by progressively smaller
170 contributions from other genes. In all, 107 proteins had LR coefficients greater than zero, thus
171 indicating greater autoantibody presence in MIS-C, and referred to here as the *classifier set*
172 (Figure 1B). The receiver operating characteristic (ROC) curve for this analysis yielded a narrow
173 range of values, with an average area under the curve (AUC) of 0.94 (Figure 1C).

174 In parallel, the Kolmogorov-Smirnov (KS) test was used to identify 661 statistically enriched
175 autoreactivities (*statistically enriched set*: those with a p-value after adjustment for multiple test
176 false discovery rates (FDR) less than 0.01). There is no agreed upon way to identify the most
177 likely putative autoantibodies associated with disease among large peptidomic datasets. To avoid
178 false positives, the intersection (n=35) of the *classifier set* and the *statistically enriched set* were
179 considered further. Of these, peptides derived from 30 different genes also satisfied an additional
180 set of conservative criteria, requiring that none be enriched (Fold-change over mock-IP (FC)>3)
181 in more than a single control, or be enriched greater than 10-fold in any number of controls,
182 hereafter referred to as the *MIS-C Set* (Figure 1B, Figure 1D). These 30 genes code for proteins
183 with diverse function and tissue expression.

184

185 ***Previously reported MIS-C autoantibodies***

186 Approximately 34 candidate autoantigens have been previously reported as associated with MIS-
187 C (20–22, 44). Of these, 33 were present in a similar proportion of MIS-C cases and at-risk
188 controls in this cohort (Supplemental Figure 1A). Autoantibodies targeting the ubiquitously
189 expressed ubiquitin protein ligase UBE3A were independently identified in this study as part of
190 both the *classifier set* and the *statistically enriched set*, but we did not include them in the *MIS-C*
191 *Set* given low positive signal in 2 controls.

192

193 Additionally, autoantibodies to the receptor antagonist IL-1Ra were previously reported in 13 of
194 21 (62%) MIS-C patients(35). In this cohort, anti-IL-1Ra antibodies were detected by PhIP-Seq
195 (z-score > 6 over at-risk control) in 6 patient samples. To further examine immune reactivity to
196 full length IL-1Ra, samples from 196 of the 199 patients in this study were used to
197 immunoprecipitate S35 radiolabeled IL-1Ra (Methods). Positive immunoprecipitation of IL-1Ra
198 (defined as greater than 3 standard deviations above mean of controls) was found in 39/196
199 (19.9%) patients with MIS-C, and the overall signal was significantly increased relative to at-risk
200 controls (p-value <0.0001). However, many MIS-C patients were treated with intravenous
201 immunoglobulin (IVIG), a blood product that has been shown to have autoantibodies(48). After
202 removing samples of MIS-C patients who were treated with IVIG prior to sample collection (61

203 remaining), the difference between samples from MIS-C patients (5/61, 8.2%) and at-risk
204 controls (1/45, 2.2%) was not significant (p-value = 0.30) (Supplemental Figure 1B).

205

206 ***MIS-C autoantigens lack tissue specific associations with clinical phenotypes***

207 Consistent with previous MIS-C reports (10, 18), this cohort was clinically heterogenous
208 (Supplemental Table 1). To determine whether specific phenotypes, including myocarditis and
209 the requirement of vasopressors, might be associated with specific autoantigens present in the
210 *MIS-C Set*, protein tissue expression levels were assigned to each autoantigen (Human Protein
211 Atlas; ProteAtlas.org), including amount of expression in cardiomyocytes and cardiac
212 endothelium. The PhIP-Seq signal for MIS-C patients with a particular phenotype was compared
213 to those MIS-C patients without the phenotype. Autoantigens with tissue specificity were not
214 enriched in those MIS-C patients with phenotypes involving said tissue. Similarly, those
215 autoantigens associated with myocarditis or vasopressor requirements did not correlate with
216 increased cardiac expression (Supplemental Figure 2).

217

218 ***Orthogonal validation of PhIP-Seq autoantigens***

219 Peptides derived from ERFL, SNX8, and KDELR1 carried the largest logistic regression
220 coefficients in the MIS-C classifier. The PhIP-Seq results were orthogonally confirmed by
221 immunoprecipitation of S35 radiolabeled full-length ERFL, SNX8, and KDELR1 (radioligand
222 binding assay (RLBA), see Methods) with patient (196 of the 199 samples used for PhIP-Seq)
223 and at-risk control (all 45) samples. Relative to at-risk controls, samples from MIS-C patients
224 significantly enriched each of the three target proteins (p-value <0.0000001 for ERFL, SNX8,
225 and KDELR1), consistent with the PhIP-Seq assay (Figure 1E). Using only the radiolabeled
226 immunoprecipitation data for these three proteins, MIS-C could be confidently classified (using
227 5-fold cross validation, iterated 1,000 times) from at-risk control sera with a ROC AUC of 0.93,
228 suggesting potential for molecular diagnostic purposes (Figure 1F).

229

230 In this cohort, IVIG was administered to 137 of the 199 patients with MIS-C prior to sample
231 collection and was absent from all 45 at-risk controls. The autoreactivity to the ERFL, SNX8,
232 and KDELR1 proteins from the 62 MIS-C patients who had not been treated with IVIG prior to
233 sample collection were compared to the at-risk controls (Supplemental Figure 3A). In contrast to
234 IL-1Ra, the differential enrichment of these three proteins remained significant (p-value <0.0001,
235 <0.00007, and <0.00011 respectively) suggesting that autoreactivity to ERFL, SNX8, and
236 KDELR1 proteins was not confounded by IVIG treatment (Supplemental Figure 3B).

237

238

239 ***Independent MIS-C cohort validation***

240 To further test the validity of these findings, an independent validation cohort consisting of
241 samples from 24 different MIS-C patients and 29 children severely ill with acute COVID-19
242 infection was acquired (Supplemental Table 2). Using the RLBA assay with full length SNX8,
243 ERFL, and KDELR1 proteins, all three target proteins were significantly enriched relative to
244 both the at-risk controls (p-value = 0.00023, 0.00004, and 0.00003 for ERFL, SNX8, and
245 KDELR1, respectively) and the severe acute COVID-19 patients (p-value = 0.007, 0.008, 0.0012
246 for ERFL, SNX8, and KDELR1, respectively) (Supplemental Figure 4A). Using a logistic
247 regression classifier that was trained on the original cohort, the ROC AUC in the validation
248 cohort for classification of MIS-C from at-risk controls was 0.84, and from severe acute pediatric

249 COVID-19 was 0.78 (Supplemental Figure 4B), suggesting that autoreactivity to these three
250 proteins is a significant feature of MIS-C separable not only from SARS-CoV-2 exposure itself,
251 but also from severe acute pediatric COVID-19.

252

253 ***MIS-C autoantibodies target a single epitope within SNX8 protein***

254 SNX8 is a protein of 465 amino acids that belongs to a family of sorting nexins involved in
255 endocytosis, endosomal sorting, and signaling(49). Publicly available expression data (Human
256 Protein Atlas; Proteinatlas.org) shows SNX8 is widely expressed across a variety of tissues
257 including the brain, heart, gastrointestinal tract, kidneys, and skin, with highest expression in
258 undifferentiated cells and immune cells. Previous work has associated SNX8 with host defense
259 against bacteria, DNA viruses, and RNA viruses (43, 50, 51). ERFL is a poorly characterized
260 protein of 354 amino acids. A survey of single cell RNA sequencing data (Human Protein Atlas;
261 Proteinatlas.org) suggests enrichment in plasma cells, B-cells, and T-cells in some tissues. Using
262 a Spearman correlation in principal component analysis (PCA) space based on tissue RNA
263 sequencing data (Human Protein Atlas; Proteinatlas.org) SNX8 has the second closest expression
264 pattern to ERFL, with a correlation of 0.81. KDELR1 is a 212 amino acid ER-Golgi transport
265 protein essential to lymphocyte development with low tissue expression specificity. All three
266 proteins are predicted or known to be intracellular, suggesting that putative autoantibodies
267 targeting these proteins are unlikely to be sufficient for disease pathology on their own.
268 However, autoantibodies targeting intracellular antigens are often accompanied by a T-cell
269 which is autoreactive to the protein from which that antigen was derived, and which targets cell
270 types expressing the protein. Of these proteins, we selected SNX8 for further investigation given
271 its enrichment in immune cells, as well as its putative role in regulating the MAVS pathway in
272 response to RNA viral infection, a pathway recently implicated in MIS-C pathology(41).

273

274 Full length SNX8 is represented in this PhIP-Seq library by 19 overlapping 49mer peptides. For
275 all but one patient sample, the peptide fragment spanning amino acid positions 25 to 73 was the
276 most enriched in the PhIP-Seq assay (Figure 2A), suggesting a common autoreactive site. To
277 narrow the portion of this peptide to a smaller fragment, a sequential alanine scan was performed
278 (Figure 2B; Methods). Using samples from six individuals with MIS-C, the critical region for
279 immunoreactivity was determined to span 9 amino acids, positions 51 through 59
280 (PSRMQMPQG). Using the wild-type 49 amino acid peptide and the version with the critical
281 region mutated to alanines, 182 of the 199 MIS-C patients and all 45 controls were assessed for
282 immunoreactivity using a split-luciferase binding assay (Methods; SLBA). We found that
283 samples from 31 of 182 (17.0%) patients with MIS-C immunoprecipitated the wildtype
284 fragment. Of these, 29 (93.5%) failed to immunoprecipitate the mutated peptide, suggesting a
285 common shared autoreactive epitope among nearly all of the MIS-C patients with anti-SNX8
286 antibodies. In contrast, only a single sample (out of 45) from the at-risk control cohort
287 immunoprecipitated the wildtype fragment in this assay (Supplemental figure 5).

288

289 ***MIS-C patients have an altered antibody response to the SARS-CoV-2 N protein***

290 To evaluate whether differences exist in the humoral immune response to SARS-CoV-2 infection
291 in patients with MIS-C relative to at-risk controls, we repeated PhIP-Seq with 181 of the original
292 199 MIS-C patients and all 45 of the at-risk controls using a previously validated library specific
293 for SARS-CoV-2(52). To discover whether certain fragments were differentially enriched by
294 either MIS-C or at-risk controls, the enrichment of each phage encoded SARS-CoV-2 peptide

295 (38 amino acids each) in each of the MIS-C patients and each at-risk control was normalized to
296 48 pre-COVID healthy controls. Three nearly adjacent peptides derived from the SARS-CoV-2
297 N protein were found to have significant differences in enrichment (KS-test, $p < 0.000001$ for
298 each of the three peptides). The first peptide, spanning amino acids 77-114, was significantly
299 enriched in the at-risk controls (representing the typical serological response in children),
300 whereas the next two fragments, spanning amino acids 134-190, were significantly enriched by
301 MIS-C patients (Figure 3A, B). This differentially reactive domain of the SARS-CoV-2 N
302 protein was termed the MIS-C associated domain of SARS-CoV-2 (MADS). The PhIP-Seq
303 results were orthogonally confirmed using the SLBA assay to measure the amount of MADS
304 peptide immunoprecipitated with samples from 16 individuals, including 11 MIS-C patients and
305 5 at-risk controls (Figure 3C). To more precisely map the critical reactive region of the
306 differentially enriched N protein peptides by MIS-C samples, peptides featuring a sliding
307 window of 10 alanine residues were used as the immunoprecipitation substrate for the SLBA
308 assay, run in parallel with the SNX8 alanine scanning peptides for three MIS-C sera samples
309 (Figure 3D). Remarkably, the critical regions identified here in both SNX8 and SARS-CoV-2 N
310 protein possessed significant similarity and can be represented by the regular expression
311 [ML]Q[ML]PQG (Figure 3E).

312

313 ***MIS-C patients have significantly increased SNX8 autoreactive T-cells***

314 In other autoimmune diseases, autoantibodies are often generated against intracellular targets, yet
315 the final effectors of cellular destruction are autoreactive T-cells(31, 52). Given evidence that
316 certain subsets of MIS-C are HLA-associated(36, 37), and that SNX8 is known to be an
317 intracellular protein, we hypothesized that MIS-C patients with anti-SNX8 antibodies may, in
318 addition to possessing SNX8 autoreactive B-cells, also possess autoreactive T-cells targeting
319 SNX8 expressing cells. To test this hypothesis, T-cells from 9 MIS-C patients (8 from SNX8
320 autoantibody positive patients and 1 who was SNX8 autoantibody negative) and 10 at-risk
321 controls (chosen randomly) were exposed to a pool of 15-mer peptides with 11 amino acid
322 overlaps that collectively tiled full length human SNX8 protein. T-cell activation was measured
323 by an activation induced marker (AIM) assay, which quantifies upregulation of three cell
324 activation markers: OX40, CD69 and CD137 (Figure 4A)(53–55). The percent of T-cells which
325 activated in response to SNX8 protein was significantly higher in MIS-C than controls (p -value
326 < 0.001) Using a positive cutoff of 3 standard deviations above the mean of the controls, 7 of the
327 9 MIS-C (78%) patients were deemed positive for SNX8 autoreactive T-cells, while no controls
328 met these criteria (Figure 4B). With respect to CD8+ and CD4+ subgroups specifically, there
329 was increased signal in MIS-C relative to controls which did not meet significance ($p=0.071$ and
330 $p=0.058$, respectively) (Supplemental Figure 6). The MIS-C patient who was seronegative for
331 the SNX8 autoantibody was also negative for SNX8 autoreactive T-cells.

332

333 ***HLA type A*02 is more likely to present the shared epitope***

334 MIS-C has been associated with HLA types A*02, B*35, and C*04(36, 37). The Immune
335 Epitope Database and Analysis Resource (IEDB.org(56)) was used to rank the MHC I peptide
336 presentation likelihoods for both SNX8 and SARS-CoV-2 N protein with respect to the MIS-C
337 associated HLA alleles. The distribution of predicted MHC I binding scores for N protein and
338 SNX8 fragments matching the [ML]Q[ML]PQG regular expression relative to fragments lacking
339 a match was compared. For HLA type A*02, predicted MHC I binding was significantly higher
340 ($p < 0.0001$ for N protein and $p = 0.001$ for SNX8) for fragments containing the putative

341 autoreactive motif. There was no statistical difference for HLA B*35 and C*04 predictions
342 (Supplemental Figure 7). Of note, of the 7 MIS-C patients with SNX8 autoreactive T-cells, 4 of
343 the patients had HLA-typing performed, and all 4 were HLA-A*02 positive (Supplemental
344 Figure 6).

345 346 ***Identification of MIS-C T-cells cross-reactive to the similarity regions of SNX8 and N protein***

347 Given the prediction that MIS-C associated HLA types preferentially display peptides containing
348 the similarity regions for both SNX8 and the SARS-CoV-2 N protein, we sought to determine
349 whether cross-reactive T-cells were present, and if they were specific to MIS-C. We therefore
350 stimulated PBMCs from 3 MIS-C patients and 3 at-risk controls with peptides from either the
351 SNX8 similarity region [MQMPQGNPL] or the SARS-CoV-2 N protein similarity region
352 [LQLPQGITL] for 7 days to enrich for CD8+ T-cells reactive to these epitopes. We then built
353 differently labeled MHCI tetramers loaded with either the SNX8 peptide [MQMPQGNPL] or the
354 SARS-CoV-2 peptide [LQLPQGITL] (Figure 4C) and measured binding to T-cells.

355
356 Each of the three MIS-C patients had multiple CD8+ T-cells which bound to both the SNX8
357 peptide and the SARS-CoV-2 peptide. None of the three at-risk controls had any cross-reactive
358 CD8+ T-cells. The percentage of CD8+ T-cells binding to each of the individual epitopes was
359 also measured (Figure 4D). The 3 MIS-C patients had multiple T-cells which bound to the N
360 protein peptide, SNX8 peptide, and both peptides (cross-reactive).

361 362 ***SNX8 peptide with similarity region is sufficient to activate T-cells***

363 Because MIS-C patients preferentially harbor T-cells which activate in response to a peptide
364 pool containing fragments spanning the entire SNX8 protein and have T-cells which are cross-
365 reactive T-cells between similarity regions of SNX8 and the N-protein, the similarity region of
366 SNX8 alone was tested for its ability to activate patient T-cells. A pool of 20 10mer peptides
367 with 9 amino acid overlaps centered on the target motif from SNX8 (collectively spanning amino
368 acids 44 through 72) was used to stimulate PBMCs from two patients with MIS-C and 4 at-risk
369 controls. Both of the MIS-C patients had activation of T-cells and none of the 4 controls had T-
370 cell activation (Supplemental figure 8).

371 372 ***RNA expression profile of SNX8 during SARS-CoV-2 infection***

373 As previously discussed, SNX8 is widely expressed across many tissue types, but most highly
374 expressed by immune cells, consistent with its known function defending against RNA viruses
375 via recruitment of MAVS(43). To further investigate the potential impact of combined B-cell and
376 T-cell autoimmunity to SNX8 in the setting of SARS-CoV-2 infection, we analyzed SNX8
377 expression from single-cell sequencing of PBMC samples from patients with severe, mild, or
378 asymptomatic COVID-19 infection, influenza infection, and uninfected healthy controls (57).
379 In the setting of SARS-CoV-2 infection, SNX8 has highest mean expression in classical and
380 non-classical monocytes and B-cells (Supplemental Figure 9A and Supplemental Figure 9B).
381 SNX8 has higher expression in individuals with SARS-CoV-2 infections compared to uninfected
382 (Supplemental Figure 9C). Within myeloid lineage cells, SNX8 expression correlates with
383 MAVS expression, and OAS1 and OAS2 (two known regulators of the MAVS pathway
384 specifically implicated in MIS-C pathogenesis(41)) expression (Supplemental Figure 9D). In
385 contrast to MAVS, SNX8 expression is inversely correlated to severity of SARS-CoV-2
386 infection, with highest expression in asymptomatic individuals. This follows a similar pattern to

387 OAS1 and OAS2. However, unlike OAS1, OAS2, and MAVS, SNX8 is preferentially expressed
388 in SARS-CoV-2 infections relative to influenza virus infection (Supplemental Figure 9E).
389

390 Discussion

391 The SARS-CoV-2 pandemic largely spared children from severe disease. One rare but notable
392 exception is MIS-C, an enigmatic and life-threatening syndrome. Children with MIS-C have
393 increased circulating inflammatory markers, dysregulated innate and adaptive immunity, and
394 evidence of autoimmunity (17–23, 37, 58). Previous studies have surfaced numerous
395 associations, but have failed to identify a direct mechanistic link between SARS-CoV-2 and
396 MIS-C. Among those previously reported associated autoantibodies (20–22, 44), only
397 autoantibodies targeting UBE3A and IL1RA were significantly enriched in this study, though
398 anti-UBE3A antibodies were found in some controls and an association with anti-IL1RA
399 antibodies were confounded by IVIG treatment.

400
401 In this study, 199 MIS-C patient samples and 45 pediatric at-risk controls were analyzed using a
402 customized human and SARS-CoV-2 proteome PhIP-seq library. In the human library, the
403 results reveal an autoreactive signature that distinguishes cases from controls, driven by
404 enrichment of peptides deriving from three proteins, including SNX8, which is expressed by
405 immune cells across multiple tissues. For SARS-CoV-2, differential enrichment between cases
406 and controls was dominated by peptides derived from the N protein. Fine epitope mapping of
407 both SNX8 and N protein identified a sequence that is highly similar, represented by the regular
408 expression [ML]Q[ML]PQG. Furthermore, CD8⁺ T-cells were found to be cross-reactive for this
409 same epitope in MIS-C cases, but not controls. These cross-reactive cells may contribute to
410 immune dysregulation through the inappropriate engagement of immune cell lineages expressing
411 SNX8. Intriguingly, we found evidence for sharing of the [ML]Q[ML]PQG epitope between
412 both B-cells and T-cells in our analysis and further study will be needed to understand this
413 apparent convergence. Importantly, there is broad evidence that in many autoimmune diseases
414 autoantibodies can target intracellular antigens, but pathology is thought to be driven by an
415 autoreactive T-cell response(31, 52).

416
417 These findings may help to clarify and connect several important known aspects of MIS-C
418 pathophysiology. Specifically, these results draw parallels to other diseases in which exposure to
419 a new antigen leads to autoimmunity, such as paraneoplastic autoimmune disease or cross-
420 reactive viral epitopes between EBV and host proteins in multiple sclerosis(24–26, 31). An
421 expansion of TRVB11-2 T-cells in MIS-C has been shown(23, 36–39), and while a superantigen
422 has been postulated, it has yet to be identified. Recent studies have shown that tissue resident T-
423 cells exhibit site-specific expansions(59), and that MIS-C patients have a distinct increase in
424 activated circulating T-cells with a tissue-resident phenotype(41), leading to speculation that
425 these T-cells may be driving the TRVB11-2 expansion. Although SNX8 is a relatively
426 understudied protein, it has been linked to the function and activity of MAVS(43). Importantly,
427 dysregulation of the MAVS antiviral pathway, by inborn errors of immunity, has been shown to
428 underly certain cases of MIS-C(41). The most straightforward connection linking MIS-C to
429 SNX8 may be through an inappropriate autoimmune response against tissues with significant
430 MAVS pathway expression, but further investigation will be needed to test this potential link.

431
432 In addition to helping contextualize previous findings, these results are the first to directly link
433 the initial SARS-CoV-2 infection and the subsequent development of MIS-C. We propose that
434 MIS-C may be the results of multiple uncommon events converging. The initial insult is likely
435 the formation of a combined B-cell and T-cell response that preferentially targets a particular

436 motif within the N protein of SARS-CoV-2. A subset of individuals may then develop a cross-
437 reactive B-cell and T-cell response to the self-protein SNX8. Interestingly, this cross-reactive
438 motif has strong binding characteristics for the MIS-C associated HLA-A*02(37), further
439 indicating that this may be an important risk factor in the development of MIS-C.

440
441 These results describe a subset of MIS-C (at least 17% positive for antibodies against SNX8),
442 indicating that other mechanisms likely exist. Antibodies against ERFL are present in many
443 children with MIS-C who do not have autoreactivity to SNX8, and ERFL has a highly similar
444 tissue RNA expression profile to SNX8 (2nd most similar among all known proteins; Human
445 Protein Atlas; Proteinatlas.org). If autoreactive T-cells to ERFL indeed also exist, they would be
446 predicted to engage a nearly identical set of cells and tissues. It is important to also consider that
447 MIS-C prevalence has rapidly decreased as an increasing number of children have developed
448 immunity through vaccination and natural SARS-CoV-2 infection. We speculate that perhaps
449 this could be related to the strong deviation of the anti-SARS CoV-2 immune response away
450 from the critical region of the N-protein that we have identified, to other major epitopes such as
451 those in the Spike protein through vaccination and past infection. Alternatively, ongoing
452 evolution of SARS-CoV-2 may include mutations in the N protein that could affect subsequent
453 antigen processing and presentation.

454
455 MIS-C is complex and more work is required to fully unravel the etiology. Why the differential
456 adaptive immune response outlined above occurs in children with MIS-C and not others remains
457 somewhat unclear. However, the results of this study, and specifically the development of
458 combined cross-reactive B-cells and T-cells, bear similarity to other notable examples of
459 molecular mimicry. Future work is needed to examine the mechanisms by which a cross-reactive
460 epitope forces a break in tolerance, which may point toward better diagnostics and therapeutic
461 interventions for many diseases with similar underlying mechanisms.

462 **Methods**

463 *Patients*

464 Patients were recruited through the prospectively enrolling multicenter Overcoming COVID-19
465 and Taking on COVID-19 Together study in the United States. The study was approved by the
466 central Boston Children's Hospital Institutional Review Board (IRB) and reviewed by IRBs of
467 participating sites with CDC IRB reliance. A total of 292 patients were enrolled into 1 of the
468 following independent cohorts between June 1, 2020 and September 9, 2021: 223 patients
469 hospitalized with MIS-C (199 in the primary discovery cohort, 24 in a separate subsequent
470 validation cohort), 29 patients hospitalized for COVID-19 in either an intensive care or step-
471 down unit (referred to as severe acute COVID-19 in this study), and 45 outpatients (referred to as
472 "at-risk controls" in this study) post-SARS-CoV-2 infections associated with mild or no
473 symptoms. The demographic and clinical data are summarized in Table I, Supplemental Table 1,
474 and Supplemental Table 2. The 2020 US Centers for Disease Control and Prevention case
475 definition was used to define MIS-C(60). All patients with MIS-C had positive SARS-CoV-2
476 serology results and/or positive SARS-CoV-2 test results by reverse transcriptase quantitative
477 PCR. All patients with severe COVID-19 or outpatient SARS-CoV-2 infections had a positive
478 antigen test or nucleic acid amplification test SARS-CoV-2. For outpatients, samples were
479 collected from 36 to 190 days after the positive test (median, 70 days after positive test;
480 interquartile range, 56-81 days). For use as controls in the SARS-CoV-2 specific PhIP-Seq,

481 plasma from 48 healthy, pre-COVID-19 controls were obtained as deidentified samples from the
482 New York Blood Center. These samples were part of retention tubes collected at the time of
483 blood donations from volunteer donors who provided informed consent for their samples to be
484 used for research.

485

486 ***DNA oligomers for split luciferase binding assays (SLBAs)***

487 DNA coding for the desired peptides for use in split luciferase binding assays were inserted into
488 split luciferase constructs containing a terminal HiBiT tag and synthesized (Twist Biosciences)
489 as DNA oligomers and verified by Twist Biosciences prior to shipment. Constructs were
490 amplified by PCR using the 5'- AAGCAGAGCTCGTTTAGTGAACCGTCAGA-3' and 5'-
491 GGCCGGCCGTTTAAACGCTGATCTT-3' primer pair.

492 For SNX8, the oligomers coded for the following sequences:

EADPPASDLPTPQAIEPQAI VQQVPAPSRMQMPQGNPLLLSHTLQELLA
AAAAAAAAAATPQAIEPQAI VQQVPAPSRMQMPQGNPLLLSHTLQELLA
EADPPAAAAAAAAAEPQAI VQQVPAPSRMQMPQGNPLLLSHTLQELLA
EADPPASDLPAAAAAAAAAAVQQVPAPSRMQMPQGNPLLLSHTLQELLA
EADPPASDLPTPQAIAAAAAAAAAAAPS RMQMPQGNPLLLSHTLQELLA
EADPPASDLPTPQAIEPQAI AAAAAAAAAAQMPQGNPLLLSHTLQELLA
EADPPASDLPTPQAIEPQAI VQQVPAAAAAAAAAANPLLLSHTLQELLA
EADPPASDLPTPQAIEPQAI VQQVPAPSRMAAAAAAAAAASHTLQELLA
EADPPASDLPTPQAIEPQAI VQQVPAPSRMQMPQGAAAAAAAAAELLA
EADPPASDLPTPQAIEPQAI VQQVPAPSRMQMPQGNPLLLAAAAAAAAA

493 For SARS-CoV-2 nucleocapsid, the oligomers coded for the following sequences:

ATEGALNTPKDHIGTRNPANNAI V LQLPQGTTLPKGFYAEGSRGGSQA
AAAAAAAAAADHIGTRNPANNAI V LQLPQGTTLPKGFYAEGSRGGSQA
ATEGAAAAAAAAAARNPANNAI V LQLPQGTTLPKGFYAEGSRGGSQA
ATEGALNTPKAAAAAAAAANNAI V LQLPQGTTLPKGFYAEGSRGGSQA
ATEGALNTPKDHIGTAAAAAAAAALQLPQGTTLPKGFYAEGSRGGSQA
ATEGALNTPKDHIGTRNPANNAI VAAAAAAAAAAGTTLPKGFYAEGSRGGSQA
ATEGALNTPKDHIGTRNPANNAI VAAAAAAAAAAKGFYAEGSRGGSQA
ATEGALNTPKDHIGTRNPANNAI V LQLPQAAAAAAAAAEGSRGGSQA
ATEGALNTPKDHIGTRNPANNAI V LQLPQGTTLPAAAAAAAAAAGSQA
ATEGALNTPKDHIGTRNPANNAI V LQLPQGTTLPKGFYAAAAAAAAA

494

495 ***DNA plasmids for radioligand binding assays (RLBAs)***

496 For radioligand binding assays, DNA expression plasmids under control of a T7 promoter and
497 with a terminal Myc-DDK tag for the desired protein were utilized. For ERFL, a custom plasmid
498 was ordered from Twist Bioscience in which a Myc-DDK-tagged full length ERFL sequence
499 under a T7 promoter was inserted into the pTwist Kan High Copy Vector (Twist Bioscience).

500 Twist Bioscience verified a sequence perfect clone by next generation sequencing prior to
501 shipment. Upon receipt, the plasmid was sequence verified by Primordium Labs. For SNX8, a
502 plasmid containing Myc-DDK-tagged full length human SNX8 under a T7 promoter was ordered
503 from Origene (RC205847) and was sequence verified by Primordium Labs upon receipt. For
504 KDELR1, a plasmid containing Myc-DDK-tagged full length human KDELR1 under a T7
505 promoter was ordered from Origene (RC205880), and was sequence verified by Primordium
506 Labs upon receipt. For IL1RN, a plasmid containing Myc-DDK-tagged full length human IL1RN
507 under a T7 promoter was ordered from Origene (RC218518), and was sequence verified by
508 Primordium Labs upon receipt.

509

510 ***Polypeptide pools for activation induced marker (AIM) assays***

511 To obtain polypeptides tiling full length SNX8 protein, 15-mer polypeptide fragments with 11
512 amino acid overlaps were ordered from JPT Peptide Technologies and synthesized. Together a
513 pool of 130 of these polypeptides (referred to as “SNX8 Pool”) spanned all known translated
514 SNX8 (the full length 465 amino acid SNX8 protein, as well as a unique region of SNX8
515 Isoform 3). A separate pool was designed to cover primarily the region of SNX8 with similarity
516 to the SARS-CoV-2 nucleocapsid protein in high resolution (referred to as “high resolution
517 epitope pool”). This pool contained 20 10-mers with 9 amino acid overlaps tiling amino acids 44
518 through 72 (IVQQVPAPSRMQMPQGNPLLSHTLQELL) of full length SNX8 protein. The
519 sequence of each of these 150 polypeptides was verified by mass spectrometry and purity was
520 calculated by high-performance liquid chromatography (HPLC).

521

522 ***Peptides for tetramer assays***

523 For use in loading tetramers, two peptides were ordered from Genemed Synthesis, Inc., as 9-
524 mers. One sequence, LQLPQGITL, corresponds to the region of the SARS-CoV-2 nucleocapsid
525 protein with similarity to human SNX8. This sequence was verified by mass spectrometry and
526 purity was calculated as 96.61% by HPLC. The other sequence, MQMPQGNPL, corresponds to
527 the region of human SNX8 protein with similarity to the SARS-CoV-2 nucleocapsid protein.
528 This sequence was verified by mass spectrometry and purity was calculated as 95.83% by HPLC.

529

530 ***Human proteome PhIP-Seq***

531 Human Proteome PhIP-Seq was performed following our previously published vacuum-based
532 PhIP-Seq protocol (45) (<https://www.protocols.io/view/scaled-high-throughput-vacuum-hip-protocol-ewov1459kvr2/v1>).

533

534
535 Our human peptidome library consists of a custom-designed phage library of 731,724 unique T7
536 bacteriophage each presenting a different 49 amino-acid peptide on its surface. Collectively these
537 peptides tile the entire human proteome including all known isoforms (as of 2016) with 25
538 amino-acid overlaps. 1 milliliter of phage library was incubated with 1 microliter of human
539 serum overnight at 4C and immunoprecipitated with 25 microliters of 1:1 mixed protein A and
540 protein G magnetic beads (Thermo Fisher, Waltham, MA, #10008D and #10009D). These beads
541 were then washed, and the remaining phage-antibody complexes were eluted in 1 milliliter of
542 E.Coli (BLT5403, EMD Millipore, Burlington, MA) at 0.5-0.7 OD and amplified by growing in
543 37C incubator. This new phage library was then re-incubated with the same individual’s serum
544 and the previously described protocol repeated. DNA was then extracted from the final phage-
545 library, barcoded, and PCR-amplified and Illumina adaptors added. Next-Generation Sequencing

546 was then performed using an Illumina sequencer (Illumina, San Diego, CA) to a read depth of
547 approximately 1 million per sample.

548

549 ***Human proteome PhIP-Seq analysis***

550 All human peptidome analysis (except when specifically stated otherwise) was performed at the
551 gene-level, in which all reads for all peptides mapping to the same gene were summed, and 0.5
552 reads were added to each gene to allow inclusion of genes with zero reads in mathematical
553 analyses. Within each individual sample, reads were normalized by converting to the percentage
554 of total reads. To normalize each sample against background non-specific binding, a fold-change
555 (FC) over mock-IP was calculated by dividing the sample read percentage for each gene by the
556 mean read-percentage of the same gene for the AG bead only controls. This FC signal was then
557 used for side-by-side comparison between samples and cohorts. FC values were also used to
558 calculate z-scores for each MIS-C patients relative to controls and for each control sample by
559 using all remaining controls. These z-scores were used for the logistic-regression feature
560 weighting. In instances of peptide-level analysis, raw reads were normalized by calculating the
561 number of reads per 100,000 reads.

562

563 ***SARS-CoV-2 proteome PhIP-Seq***

564 SARS-CoV-2 Proteome PhIP-Seq was performed as previously described(51). Briefly, 38 amino
565 acids fragments tiling all open reading frames from SARS-CoV-2, SARS-CoV-1, and 7 other
566 CoVs were expressed on T7 bacteriophage with 19 amino acid overlaps. 1 milliliter of phage
567 library was incubated with 1 microliter of human serum overnight at 4C and immunoprecipitated
568 with 25 microliters of 1:1 mixed protein A and protein G magnetic beads (Thermo Fisher,
569 Waltham, MA, #10008D and #10009D). Beads were washed 5 times on a magnetic plate using
570 a P1000 multichannel pipette. The remaining phage-antibody complexes were eluted in 1
571 milliliter of E.Coli (BLT5403, EMD Millipore, Burlington, MA) at 0.5-0.7 OD and amplified by
572 growing in 37C incubator. This new phage library was then re-incubated with the same
573 individual's serum and the previously described protocol repeated for a total of 3 rounds of
574 immunoprecipitations. DNA was then extracted from the final phage-library, barcoded, and
575 PCR-amplified and Illumina adaptors added. Next-Generation Sequencing was then performed
576 using an Illumina sequencer (Illumina, San Diego, CA) to a read depth of approximately 1
577 million per sample.

578

579 ***Coronavirus proteome PhIP-Seq analysis***

580 To account for differing read depths between samples, the total number of reads for each peptide
581 fragment was converted to the number of reads per 100k (RPK). To calculate normalized
582 enrichment relative to pre-COVID controls (FC > Pre-COVID), the RPK for each peptide
583 fragment within each sample was divided by the mean RPK of each peptide fragment among all
584 pre-COVID controls. These FC > Pre-COVID values were used for all subsequent analyses as
585 described in the text and figures.

586

587 ***Radioligand binding assay (RLBA)***

588 Radioligand binding assays were performed as previously described(45, 46). Briefly, DNA
589 plasmids containing full-length cDNA under the control of a T7 promoter for each of the
590 validated antigens (see RLBA plasmids above) were verified by Primordium Labs sequencing.
591 The respective DNA templates were used in the T7 TNT in vitro transcription/translation kit

592 (Promega, Madison, WI; #L1170) using [35S]-methionine (PerkinElmer, Waltham, MA;
593 #NEG709A). Respective protein was column-purified on Nap-5 columns (GE healthcare,
594 Chicago, IL; #17-0853-01), and equal amounts of protein (approximately 35,000 counts per
595 minute (cpm)) were incubated overnight at 4 degrees C with 2.5 ul of serum or 1 ul anti-Myc
596 positive control antibody (Cell Signaling Technology, #2272 S). Immunoprecipitation was then
597 performed on 25 microliters of Sephadex protein A/G beads (Sigma Aldrich, St. Louis, MO;
598 #GE17-5280-02 and #GE17-0618-05, 4:1 ratio) in 96-well polyvinylidene difluoride filtration
599 plates (Corning, Corning, NY; #EK-680860). After thoroughly washing, the counts per minute
600 (cpm) of immunoprecipitated protein was quantified using a 96-well Microbeta Trilux liquid
601 scintillation plate reader (Perkin Elmer).

602

603 ***Split luciferase binding assay (SLBA)***

604 SLBA was performed as described in Rackaityte et. al(61). A detailed SLBA protocol is
605 available on protocols.io at: [dx.doi.org/10.17504/protocols.io.4r3l27b9pg1y/v1](https://doi.org/10.17504/protocols.io.4r3l27b9pg1y/v1).

606

607 Briefly, the DNA oligomers listed above (SLBA DNA oligomers) were amplified by PCR using
608 the primer pairs listed above (SLBA DNA oligomers). Unpurified PCR product was used as
609 input in the T7 TNT in vitro transcription/translation kit (Promega, Madison, WI; #L1170) and
610 Nano-Glo HiBit Lytic Detection System (Promega Cat No. N3040) was used to measure relative
611 luciferase units (RLU) of translated peptides in a luminometer. Equal amounts of protein (in the
612 range of 2e6 to 2e7 RLU) were incubated overnight with 2.5 ul patient sera or 1ul anti-HiBit
613 positive control antibody (Promega, Madison, WI; #CS2006A01) at 4 C. Immunoprecipitation
614 was then performed on 25 microliters of Sephadex protein A/G beads (Sigma Aldrich, St. Louis,
615 MO; #GE17-5280-02 and #GE17-0618-05, 1:1 ratio) in 96-well polyvinylidene difluoride
616 filtration plates (Corning, Corning, NY; #EK-680860). After thoroughly washing, luminescence
617 was measured using Nano-Glo HiBit Lytic Detection System (Promega Cat No. N3040) in a
618 luminometer.

619

620 ***Activation induced marker (AIM) assay***

621 Peripheral blood mononuclear cells (PBMCs) were obtained from 10 patients with MIS-C and 10
622 controls for use in the AIM assay. PBMCs were thawed, washed, resuspended in serum-free
623 RPMI medium, and plated at a concentration of 1e10⁶ cell/well in a 96-well round-bottom plate.
624 For each individual, PBMCs were stimulated for 24-hours with either the SNX8 pool (see above)
625 at a final concentration of 1 ug/mL/peptide in 0.2% DMSO, or a vehicle control containing 0.2%
626 DMSO only. For 4 of the controls and 2 of the MIS-C patients, there were sufficient PBMCs for
627 an additional stimulation condition using the SNX8 high resolution epitope pool (see above) also
628 at a concentration of 1 ug/mL/peptide in 0.2% DMSO for 24-hours. Following the stimulation,
629 cells were washed with FACS buffer (Dulbecco's PBS without calcium or magnesium, 0.1%
630 sodium azide, 2 mM EDTA, 1% FBS) and stained with the following antibody panel for 20
631 minutes at 4 degrees and then flow cytometry analysis was immediately performed:

632

Antibody Target	Clone	Fluorophore	Vendor	Catalog #
CD3	OKT3	Alexa 647	BioLegend	317312
CD4	OKT4	Alexa 488	BioLegend	317420
CD8	SK1	Alexa 700	BioLegend	344724
OX-40 (CD134)	ACT35	PE-Dazzle 594	BioLegend	350020

CD69	FN-50	PE	BioLegend	310906
CD137 (4-1BB)	4B4-1	BV421	BioLegend	309820
CD14	HCD14	PerCP-Cy5.5	BioLegend	325622
CD16	B73.1	PerCP-Cy5.5	BioLegend	360712
CD19	HIB19	PerCP-Cy5.5	BioLegend	302230
Live/dead dye		eFluor 506	Invitrogen	65-0866-14

633
 634 The AIM analysis was performed using FlowJo software using the gating strategy shown in
 635 Supplemental Figure 10A. All gates were fixed within each condition of each sample. Activated
 636 CD4 T-cells were defined as those which were co-positive for OX40 and CD137. Activated CD8
 637 T-cells were defined as those which were co-positive for CD69 and CD137. Gating thresholds
 638 for activation were defined by the outer limits of signal in the vehicle controls allowing for up to
 639 2 outlier cells. Frequencies were calculated as a percentage of total CD3 positive cells (T-cells).
 640 Two MIS-C samples had insufficient total events captured by flow cytometry (total of 5,099 and
 641 4,919 events, respectively) and were therefore removed from analysis.

642 **Tetramer Assay**

643 PBMCs from 2 MIS-C patients with HLA-A*02:01 (1 identified by PAXGene genotyping, 1 by
 644 serotyping) and 1 MIS-C patient with HLA-B*35:01 (identified by PAXGene genotyping), and 3
 645 at-risk controls with HLA-A*02:01 (identified by serotyping) were thawed, washed, and put into
 646 culture with media containing recombinant human IL-2 at 10 ng/mL in 96-well plates. Peptide
 647 fragments (details above) LQLPQGITL and MQMPQGNPL were then added to PBMCs to a
 648 final concentration of 10 µg/mL/peptide and incubated (37C, 5% CO₂) for 7 days.

650
 651 Following the 7 days of incubation, a total of 8 pMHC I tetramers were generated from UV-
 652 photolabile biotinylated monomers, 4 each from HLA-A*02:01 and HLA-B*35:01 (NIH
 653 Tetramer Core). Peptides were loaded via UV peptide exchange. Tetramerization was carried out
 654 using streptavidin conjugated to fluorophores PE and APC or BV421 followed by quenching
 655 with 500µM D-biotin similar to our previously published methods(62, 63). Tetramers were then
 656 pooled together as shown below:

657 **HLA-A*02:01 Pool**

Protein	Epitope	MHC I restriction	Fluorophore
SARS-CoV-2 NP	LQLPQGITL	A*02:01	PE
SARS-CoV-2 NP	LQLPQGITL	A*02:01	APC
SNX8	MQMPQGNPL	A*02:01	PE
SNX8	MQMPQGNPL	A*02:01	BV421

660 **HLA-B*35:01 Pool**

Protein	Epitope	MHC I restriction	Fluorophore
SARS-CoV-2 NP	LQLPQGITL	B*35:01	PE
SARS-CoV-2 NP	LQLPQGITL	B*35:01	APC
SNX8	MQMPQGNPL	B*35:01	PE
SNX8	MQMPQGNPL	B*35:01	BV421

659
 660
 661

662

663 All PBMCs were then treated with 100 nM Dasatinib (StemCell) for 30 min at 37 °C followed
664 by staining (no wash step) with the respective tetramer pool corresponding to their HLA
665 restriction (final concentration, 2 to 3 µg/ml) for 30 min at room temperature. Cells were then
666 stained with the following cell surface markers for 20 minutes, followed by immediate analysis
667 on a flow cytometer:
668

Antibody Target	Clone	Fluorophore	Vendor	Catalog #
CD8	SK1	Alexa 700	BioLegend	357404
CD4	RPA-T4	PerCP-Cy5.5	BioLegend	300530
CD14	HCD14	PerCP-Cy5.5	BioLegend	325622
CD16	B73.1	PerCP-Cy5.5	BioLegend	360712
CD19	HIB19	PerCP-Cy5.5	BioLegend	302230
Streptavidin		PE	Invitrogen	S866
Streptavidin		APC	Invitrogen	S868
Streptavidin		BV421	BioLegend	405225
Live/dead dye		eFluor 506	Invitrogen	65-0866-14

669
670 The gating strategy is outlined in Supplemental Figure 10B. A stringent tetramer gating strategy
671 was used to identify cross-reactive T-cells, whereby CD8+ T-cells were required to be triple-
672 positive for PE, APC, and BV421 labels (i.e. a single CD8 T-cell bound to PE conjugated
673 LQLPQGITL and/or PE conjugated MQMPQGNPL in addition to APC-conjugated
674 LQLPQGITL and BV421 conjugated MQMPQGNPL).

675
676 Serotyping was performed using an anti-HLA-A2 antibody (FITC anti-human HLA-A2
677 Antibody, Clone BB7.2, BioLegend, Cat#343303), and pertinent results are shown in
678 Supplemental Figure 10C.

679 **Single Cell RNA Sequencing Analysis**

680 To assess the cell-type specificity in a relevant disease context, we analyzed SNX8 expression
681 from a single-cell sequencing of PBMC samples from patients with severe, mild, or
682 asymptomatic COVID-19 infection, Influenza infection and healthy controls(57). Gene
683 expression data from 59,572 pre-filtered cells was downloaded from the GEO database under
684 accession [GSE149689](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE149689) for analysis and downstream processing with scanpy(64). Cells with (i)
685 less than 1000 total counts, (ii) less than 800 expressed genes and (iii) more than 3000 expressed
686 genes were filtered out as further quality control, leaving 42,904 cells for downstream analysis.
687 Gene expression data were normalized to have 10,000 counts per cell and were $\log_1 P$
688 transformed. Highly variable genes were calculated using the scanpy function
689 `highly_variable_genes` using Seurat flavor with the default parameters (`min_mean = 0.0125`,
690 `max_mean = 3`, and `min_disp = 0.5`)(65). Only highly variable genes were used for further
691 analysis. The total number of counts per cell was regressed out, and the gene expression matrix
692 was scaled using the scanpy function `scale` with `max_value = 10`. Dimensionality reduction was
693 performed using principal components analysis with 50 principal components. Batch balanced
694 kNN (k-nearest neighbors), implemented with scanpy's function `bbknn`, was used to compute
695 each cell's top neighbors and normalize batch effects(66). The batch-corrected cells were
696 clustered using the Leiden algorithm and projected into two dimensions with uniform manifold
697 approximation and projection (UMAP) for visualization. Initial cluster identity was determined
698

699 by finding marker genes with differential expression analysis performed using a *t* test on log₁ *P*-
 700 transformed raw counts with the scanpy function rank_genes_groups(67, 68).

701

702 **Statistical methods**

703 All statistical analysis was performed in Python using the Scipy Stats package. For comparisons
 704 of distributions of PhIP-Seq enrichment between two groups, a non-parametric Kolmogorov-
 705 Smirnov test was utilized. For logistic regression feature weighting, the Scikit-learn package(69)
 706 was used, and logistic regression classifiers were applied to z-scored PhIP-Seq values from
 707 individuals with MIS-C versus at-risk controls. A liblinear solver was used with L1
 708 regularization, and the model was evaluated using a five-fold cross-validation (4 of the 5 for
 709 training, 1 of the 5 for testing). For RLBA and SLBA, first an antibody index was calculated
 710 as follows: (sample value – mean blank value) / (positive control antibody values – mean blank
 711 values). For the alanine mutagenesis scans, blank values of each construct were combined, and a
 712 single mean was calculated. A normalization function was then applied to the experimental
 713 samples only (excluding antibody only controls) to create a normalized antibody index ranging
 714 from 0 to 1. Comparisons between two groups of samples were performed using a Mann-
 715 Whitney U test. An antibody was considered to be “positive” when the normalized antibody
 716 index in a sample was greater than 3 standard deviations above the mean of controls. When
 717 comparing two groups of normally distributed data, a T-test was performed. P-values: ns > 0.05,
 718 * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001, ***** < 0.00001.

719

720 **Supplemental Tables**

721

722 **Supplemental Table 1: Phenotypic data for MIS-C patients.**

723

Organ System Involvement (number reporting)	Phenotype Present	Percent
Respiratory		
Oxygen requirement (198)	139	70.2
Bronchospasm (161)	2	1.2
Acute Respiratory Distress Syndrome (ARDS) (198)	24	12.1
Cardiac		
Vasoactive support (198)	124	62.6
Myocarditis (199)	115	57.8
Elevated Troponin (197)	128	65
Neurologic		
Any neurologic symptoms (197)	22	11.2
Encephalitis (197)	2	1
Gastrointestinal (196)	66	33.7
Hematologic (197)	22	11.2
Rheumatologic		
Arthritis (195)	9	4.6
Myositis (194)	27	12.9
Mucocutaneous		

Conjunctivitis (197)	105	53.3
Oral Mucosal Changes (198)	76	38.4
Rash (197)	106	53.8

724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748

Table Definitions:

Oxygen requirement; receipt of any oxygen support at any time during hospitalization. Bronchospasm; severe bronchospasm requiring continuous bronchodilators. Acute Respiratory Distress Syndrome (ARDS); onset of hypoxemia was acute (during this illness), chest imaging findings of new infiltrates (unilateral or bilateral), respiratory failure not fully explained by cardiac failure or fluid overload, PaO₂/FiO₂ ratio < 300 or SpO₂/FiO₂ < 264 (if SpO₂ < 97), on CPAP > 5 cm H₂O or BiPAP or Invasive Mechanical Ventilation. Vasoactive support; receipt of vasoactive infusions (at any time during hospitalization) including: Dopamine, Dobutamine, Epinephrine, Norepinephrine, Phenylephrine, Milrinone, Vasopressin (for hypotension, not diabetes insipidus). Myocarditis; myocarditis diagnosed during hospital stay and adjudicated by outside panel of cardiologists. Elevated troponin; based on site-specific cutoff. Any neurologic symptoms; suspected central nervous system infection, stroke or intracranial hemorrhage (at presentation or during hospitalization), seizure (at presentation or during hospitalization), coma or unresponsive, receipt of neurodiagnostic imaging (CT, MRI, or LP), encephalitis, decreased hearing, decreased vision, iritis or uveitis. Gastrointestinal; appendicitis, diarrhea (at presentation or during hospitalization), abdominal pain (at presentation or during hospitalization), gallbladder hydrops or edema, pancreatitis, hepatitis, nausea/loss of appetite at presentation, vomiting at presentation. Hematologic; anemia with hemoglobin <9 g/dL, minimum white blood cells <4 x 10³ cells/μL, minimum platelets <150 x 10³ cells/μL, deep vein thrombosis, pulmonary embolism, hemolysis, bleeding, ischemia of an extremity. Oral Mucosal Changes; erythema of lips or oropharynx, strawberry tongue, or drying or fissuring of the lips.

Supplemental Table 2: Clinical characteristics of validation cohorts

	Severe Acute COVID-19	MIS-C Validation
Number	29	24
Male sex (%)	14 (48.3)	16 (66.7)
Median age in years (median, IQR)	11.4 (11.4)	7.7 (8.6)
Race and ethnicity (%)		
White, non-Hispanic	14 (48.3)	3 (12.5)
Black, non-Hispanic	4 (13.8)	8 (33.3)
Hispanic or Latino	9 (31.0)	13 (54.2)
Other race, non-Hispanic	2 (6.9)	0 (0.0)
Underlying conditions (%)		
None	9 (31.0)	13 (54.2%)
Obesity*	8 (27.6)	7 (29.2)
Asthma	3 (10.3)	2 (8.3)
Cardiovascular	1 (3.4)	0 (0.0)
Immunocompromise	1 (3.4)	0 (0.0)

Autoimmune condition	0 (0.0)	0 (0.0)
Malignancy	1 (3.4)	0 (0.0)
Interventions (%)		
ICU admission	22 (75.9)	11 (45.8)
Shock requiring vasopressors	11 (37.9)	0 (0.0)
Mechanical ventilation	6 (20.7)	2 (8.3)

749 *Does not include n=4 acute COVID-19 patients and n=1 MIS-C patients under 2 years of age.

750 **Acknowledgements.** The following members of the Overcoming COVID-19 Network Study
751 Group Investigators (presented alphabetically by state) were all closely involved with the design,
752 implementation, and oversight of the Overcoming COVID-19 study as well as collecting patient
753 samples and data. *Alabama:* Children’s of Alabama, Birmingham: Michele Kong, MD, Heather
754 Kelley, RN, BSN; Meghan Murdock, RN, BSN; Candice Colston. *Arizona:* Katri V. Typpo,
755 MD. *Arkansas:* Arkansas Children’s Hospital, Little Rock: Katherine Irby, MD; Ronald C.
756 Sanders Jr, MD, MS; Masson Yates; Chelsea Smith. *California:* UCSF Benioff Children’s
757 Hospital Oakland, Oakland: Natalie Z. Cvijanovich, MD; UCSF Benioff Children’s Hospital,
758 San Francisco: Matt S. Zinter, MD. *Colorado:* Aline B. Maddux, MD, MSCS, Emily Port, BA,
759 PMP; Rachel Mansour, BSN, RN, CPN; Sara Shankman, DNP, CPNC-AC, Natasha Baig,
760 MBBS, Frances Zorensky, BS. *Florida:* Holtz Children’s Hospital, Miami: Paula S. Espinal,
761 MD, MPH; Brandon Chatani, MD; Gwenn McLaughlin, MD, MSPH. *Georgia:* Children’s
762 Healthcare of Atlanta at Egleston, Atlanta: Keiko M. Tarquinio, MD; Kaitlin Jones, MSN, RN,
763 CCRP. *Illinois:* Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago: Bria M.
764 Coates, MD. *Indiana:* Riley Children’s Hospital, Indianapolis: Courtney M. Rowan, MD,
765 MScr. *Massachusetts:* Boston Children’s Hospital, Boston: Adrienne G. Randolph, MD;
766 Margaret M. Newhams, MPH; Suden Kucukak, MD; Tanya Novak, PhD; Elizabeth R.
767 McNamara BSN, RN; Hye Kyung Moon, MA; Takuma Kobayashi BS; Jeni Melo, BS; Sergio R.
768 Jackson, MS; Marah Kiana Echon Rosales, BS; Cameron Young, BS; Sabrina R. Chen, BS;
769 Janet Chou, MD; Rezende Da Costa Aguiar, PhD; Maria Gutierrez-Arcelus, PhD, Megan Elkins,
770 MHS. Taking On COVID-19 Together team: David Williams, MD; Lucinda Williams, DNP,
771 MSN, RN, PNP, NE-BC; Leah Cheng, MA; Yubo Zhang, BS; Danielle Crethers, BA; Debra
772 Morley, PhD; Sarah Steltz, MPH; Kelly Zakar, MSN, RN, PPCNP-BC; Myriam A. Armant,
773 PhD; Felicia Ciuculescu, MD; *Michigan:* University of Michigan C. S. Mott Children’s Hospital,
774 Ann Arbor: Heidi R. Flori, MD, FAAP; Mary K. Dahmer, PhD. *Minnesota:* Mayo Clinic,
775 Rochester: Emily R. Levy, MD, FAAP; Supriya Behl, MSc; Noelle M. Drapeau, BA.
776 *Mississippi:* Charlotte V. Hobbs, MD *Missouri:* Children’s Mercy Hospital, Kansas City:
777 Jennifer E. Schuster, MD; Abigail Kietzman BS; Shannon Hill, BSN. *Nebraska:* Children’s
778 Hospital & Medical Center, Omaha: Melissa L. Cullimore, MD, PhD; Russell J. McCulloh,
779 MD. *New Jersey:* Cooperman Barnabas Medical Center, Livingston: Shira J. Gertz, MD. *North*
780 *Carolina:* University of North Carolina, Chapel Hill: Stephanie P. Schwartz, MD; Tracie C.
781 Walker, MD. *Ohio:* Akron Children’s Hospital, Akron: Ryan A. Nofziger, MD; Cincinnati
782 Children’s Hospital, Cincinnati: Mary Allen Staat, MD, MPH; Chelsea C. Rohlfs, BS,
783 MBA. *Pennsylvania:* Children’s Hospital of Philadelphia, Philadelphia: Julie C. Fitzgerald, MD,
784 PhD, MSCE; Ryan Burnett, BS, Jenny Bush, RNC, BSN. *South Carolina:* MUSC Shawn Jenkins
785 Children’s Hospital, Charleston: Elizabeth H. Mack, MD, MS; Nelson Reed,
786 MD. *Tennessee:* Monroe Carell Jr Children’s Hospital at Vanderbilt, Nashville: Natasha B.

787 Halasa, MD, MPH. *Texas*: Texas Children's Hospital and Baylor College of Medicine, Houston:
788 Laura L. Loftis, MD. *Utah*: Primary Children's Hospital and University of Utah, Salt Lake City:
789 Hillary Crandall, MD, PhD; Kwabena Krow Ampofo, MD.

790 Members of the US Centers for Disease Control and Prevention COVID-19 Response Team on
791 the Overcoming COVID-19 Study were Laura D. Zambrano, PhD, MPH, Manish M. Patel, MD,
792 MPH, and Angela P. Campbell, MD, MPH.

793 The authors acknowledge the New York Blood Center for contributing pre-COVID-19 healthy
794 donor blood samples which were used as controls for the SARS-CoV-2 library PhIP-Seq.

795 The authors acknowledge the contributions of Weston Browne and Sam Pleasure, MD, PhD for
796 their work investigating potential central nervous system specific autoimmunity in MIS-C; Tirtha
797 Kharel, BS, for his help designing Python code used in the analysis; David Blauvelt, MD, for his
798 ideas regarding the application of advanced statistics to PhIP-Seq data analysis.

799 Biorender (Biorender.com) was used to build graphics for Figure 1A and Figure 4C.

800 **Disclaimer:** The findings and conclusions in this report are those of the authors and do not
801 necessarily represent the views of the US Centers for Disease Control and Prevention.

802 **Contributions:**

803 Conceptualization: A.B., J.J.S.Jr., S.E.V., J.C., A.G.R., M.S.A., J.L.D. Methodology: A.B.,
804 J.J.S.Jr., S.E.V., E.R., C.R.Z., A.F.K., J.V.R., J.C., A.G.R., M.S.A., J.L.D. Performed or
805 contributed to experiments: A.B., J.J.S.Jr., S.E.V., A.M., C.Y.W., A.S., J.V.P., D.J.L.Y., H.K.,
806 C.M.B. Formal analysis: A.B., J.J.S.Jr., H.S.M., A.F.K. Patient sample and clinical data
807 acquisition: K.Z., T.N., L.D.Z., A.P.C., A.G.R.K.L.M., L.L.L., C.V.H., K.M.T., M.K., J.C.F., P.S.E.,
808 T.C.W., S.P.S., H.C., K.I., M.A.S., C.M.R., J.E.S., N.B.H., S.J.G., E.H.M., A.B.M., N.Z.C.,
809 M.S.Z. Clinical data curation: T.N., A.G.R. Writing (original draft): A.B., H.M., J.L.D. Writing
810 (review and editing): A.B., J.C., T.N., H.M., L.D.Z., A.P.C., A.G.R., M.R.W., M.S.A., J.L.D.
811 Supervision: J.C., A.G.R., M.S.A., J.L.D.

812 **Funding:**

813 This work was supported by the Pediatric Scientist Development Program and the Eunice
814 Kennedy Shriver National Institute of Child Health and Human Development (K12-HD000850
815 to A.B.), and the Chan Zuckerberg Biohub SF (J.L.D. and M.S.A.). Overcoming COVID-19
816 Study Network enrollment, patient data, and specimen collections supported by the CDC
817 contracts 75D30120C07725, 75D30121C10297 and 75D30122C13330 from the Centers for
818 Disease Control and Prevention to Boston Children's Hospital to A.G.R. and the National
819 Institute of Allergy and Infectious Diseases (R01AI154470) to A.G.R. Patient clinical data and
820 specimens also collected at Boston Children's Hospital for the Taking on COVID-19 Together
821 (TOCT) study supported in part by the Boston Children's Hospital Emerging Pathogens and

822 Epidemic Response Cluster of Clinical Research Excellence and the Institutional Centers for
823 Clinical and Translational Research to A.G.R. and K.L.M.

824 **Competing Interests:**

825
826 J.D.R. reports being a founder and paid consultant for Delve Bio, Inc., and a paid consultant for
827 the Public Health Company and Allen & Co. M.A.S. receives unrelated research funding from
828 the NIH, the CDC, Cepheid and Merck and unrelated Honoraria from UpToDate, Inc. M.R.W.
829 receives unrelated research grant funding from Roche/Genentech and Novartis, and received
830 speaking honoraria from Genentech, Takeda, WebMD, and Novartis. J.C. reports consulting fees
831 from GLG group, payments from Elsevier for work as an Associate Editor, a patent pending for
832 methods and compositions for treating and preventing T cell-driven diseases, payments related to
833 participation on a Data Safety Monitoring Board or Advisory Board for Enzyvant and is a
834 member of the Diagnostic Laboratory Immunology Committee of the Clinical Immunology
835 Society. M.S.Z. receives unrelated funding from NHLBI and consults for Sobi. N.B.H. reports
836 unrelated previous grant support from Sanofi and Quidel, and current grant support from Merck.
837 C.V.H. reports being a speaker for Biofire, and a reviewer for UpToDate, Inc, and Dynamed.com.
838 A.G.R. receives royalties as a section editor for Pediatric Critical Care Medicine UpToDate, Inc,
839 and also received Honoraria for MIS-C-related Grand Round Presentations. A.G.R. is also on the
840 medical advisor board of Families Fighting Flu and is Chair of the International Sepsis Forum
841 which is supported by industry and has received reagents from Illumina, Inc.

842 **Corresponding authors:**

843 Correspondence to Joseph L. DeRisi and Mark S. Anderson.

844 **References**

- 845
846 1. M. O’Driscoll, G. Ribeiro Dos Santos, L. Wang, D. A. T. Cummings, A. S. Azman, J. Paireau, A. Fontanet, S.
847 Cauchemez, H. Salje, Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature*. **590**, 140–145
848 (2021).
- 849 2. E. J. Williamson, A. J. Walker, K. Bhaskaran, S. Bacon, C. Bates, C. E. Morton, H. J. Curtis, A. Mehrkar, D.
850 Evans, P. Inglesby, J. Cockburn, H. I. McDonald, B. MacKenna, L. Tomlinson, I. J. Douglas, C. T. Rentsch, R.
851 Mathur, A. Y. S. Wong, R. Grieve, D. Harrison, H. Forbes, A. Schultze, R. Croker, J. Parry, F. Hester, S.
852 Harper, R. Perera, S. J. W. Evans, L. Smeeth, B. Goldacre, Factors associated with COVID-19-related death
853 using OpenSAFELY. *Nature*. **584**, 430–436 (2020).
- 854 3. P. Brodin, Immune determinants of COVID-19 disease presentation and severity. *Nat. Med.* **27**, 28–33 (2021).
- 855 4. X. Lu, L. Zhang, H. Du, J. Zhang, Y. Y. Li, J. Qu, W. Zhang, Y. Wang, S. Bao, Y. Li, C. Wu, H. Liu, D. Liu, J.
856 Shao, X. Peng, Y. Yang, Z. Liu, Y. Xiang, F. Zhang, R. M. Silva, K. E. Pinkerton, K. Shen, H. Xiao, S. Xu, G.
857 W. K. Wong, Chinese Pediatric Novel Coronavirus Study Team, SARS-CoV-2 Infection in Children. *N. Engl.*
858 *J. Med.* **382**, 1663–1665 (2020).
- 859 5. F. Götzinger, B. Santiago-García, A. Noguera-Julián, M. Lanaspá, L. Lancella, F. I. Calò Carducci, N.
860 Gabrovská, S. Velizarova, P. Prunk, V. Osterman, U. Krivec, A. Lo Vecchio, D. Shingadia, A. Soriano-
861 Arandes, S. Melendo, M. Lanari, L. Pierantoni, N. Wagner, A. G. L’Huillier, U. Heininger, N. Ritz, S. Bandi,
862 N. Krajcar, S. Roglić, M. Santos, C. Christiaens, M. Creuven, D. Buonsenso, S. B. Welch, M. Bogyi, F.

- 863 Brinkmann, M. Tebruegge, ptbnet COVID-19 Study Group, COVID-19 in children and adolescents in Europe:
864 a multinational, multicentre cohort study. *Lancet Child Adolesc Health.* **4**, 653–661 (2020).
- 865 6. R. M. Viner, O. T. Mytton, C. Bonell, G. J. Melendez-Torres, J. Ward, L. Hudson, C. Waddington, J. Thomas,
866 S. Russell, F. van der Klis, A. Koirala, S. Ladhani, J. Panovska-Griffiths, N. G. Davies, R. Booy, R. M. Eggo,
867 Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A
868 Systematic Review and Meta-analysis. *JAMA Pediatr.* **175**, 143–156 (2021).
- 869 7. J. Chou, P. G. Thomas, A. G. Randolph, Immunology of SARS-CoV-2 infection in children. *Nat. Immunol.* **23**,
870 177–185 (2022).
- 871 8. L. S. Shekerdemian, N. R. Mahmood, K. K. Wolfe, B. J. Riggs, C. E. Ross, C. A. McKiernan, S. M.
872 Heidemann, L. C. Kleinman, A. I. Sen, M. W. Hall, M. A. Priestley, J. K. McGuire, K. Boukas, M. P. Sharron,
873 J. P. Burns, International COVID-19 PICU Collaborative, Characteristics and Outcomes of Children With
874 Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units.
875 *JAMA Pediatr.* **174**, 868–873 (2020).
- 876 9. E. Whittaker, A. Bamford, J. Kenny, M. Kafrou, C. E. Jones, P. Shah, P. Ramnarayan, A. Fraisse, O. Miller,
877 P. Davies, F. Kucera, J. Brierley, M. McDougall, M. Carter, A. Tremoulet, C. Shimizu, J. Herberg, J. C. Burns,
878 H. Lyall, M. Levin, PIMS-TS Study Group and EUCLIDS and PERFORM Consortia, Clinical Characteristics
879 of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-
880 CoV-2. *JAMA.* **324**, 259–269 (2020).
- 881 10. L. R. Feldstein, M. W. Tenforde, K. G. Friedman, M. Newhams, E. B. Rose, H. Dapul, V. L. Soma, A. B.
882 Maddux, P. M. Mourani, C. Bowens, M. Maamari, M. W. Hall, B. J. Riggs, J. S. Giuliano Jr, A. R. Singh, S.
883 Li, M. Kong, J. E. Schuster, G. E. McLaughlin, S. P. Schwartz, T. C. Walker, L. L. Loftis, C. V. Hobbs, N. B.
884 Halasa, S. Doymaz, C. J. Babbitt, J. R. Hume, S. J. Gertz, K. Irby, K. N. Clouser, N. Z. Cvijanovich, T. T.
885 Bradford, L. S. Smith, S. M. Heidemann, S. P. Zackai, K. Wellnitz, R. A. Nofziger, S. M. Horwitz, R. W.
886 Carroll, C. M. Rowan, K. M. Tarquinio, E. H. Mack, J. C. Fitzgerald, B. M. Coates, A. M. Jackson, C. C.
887 Young, M. B. F. Son, M. M. Patel, J. W. Newburger, A. G. Randolph, Overcoming COVID-19 Investigators,
888 Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in
889 Children (MIS-C) Compared With Severe Acute COVID-19. *JAMA.* **325**, 1074–1087 (2021).
- 890 11. J. Y. Abrams, M. E. Oster, S. E. Godfred-Cato, B. Bryant, S. D. Datta, A. P. Campbell, J. W. Leung, C. A.
891 Tsang, T. J. Pierce, J. L. Kennedy, T. A. Hammett, E. D. Belay, Factors linked to severe outcomes in
892 multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study.
893 *Lancet Child Adolesc Health.* **5**, 323–331 (2021).
- 894 12. covid-19-pediatric-multi-system-inflammatory-syndrome.pdf (available at
895 [https://www1.nyc.gov/assets/doh/downloads/pdf/han/alert/2020/covid-19-pediatric-multi-system-](https://www1.nyc.gov/assets/doh/downloads/pdf/han/alert/2020/covid-19-pediatric-multi-system-inflammatory-syndrome.pdf)
896 [inflammatory-syndrome.pdf](https://www1.nyc.gov/assets/doh/downloads/pdf/han/alert/2020/covid-19-pediatric-multi-system-inflammatory-syndrome.pdf)).
- 897 13. S. Riphagen, X. Gomez, C. Gonzalez-Martinez, N. Wilkinson, P. Theocharis, Hyperinflammatory shock in
898 children during COVID-19 pandemic. *Lancet.* **395** (2020), pp. 1607–1608.
- 899 14. R. M. Viner, E. Whittaker, Kawasaki-like disease: emerging complication during the COVID-19 pandemic.
900 *Lancet.* **395** (2020), pp. 1741–1743.
- 901 15. L. Verdoni, A. Mazza, A. Gervasoni, L. Martelli, M. Ruggeri, M. Ciuffreda, E. Bonanomi, L. D’Antiga, An
902 outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an
903 observational cohort study. *Lancet.* **395**, 1771–1778 (2020).
- 904 16. F. Sperotto, K. G. Friedman, M. B. F. Son, C. J. VanderPluym, J. W. Newburger, A. Dionne, Cardiac
905 manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive
906 review and proposed clinical approach. *Eur. J. Pediatr.* **180**, 307–322 (2021).



- 907 17. C. Diorio, S. E. Henrickson, L. A. Vella, K. O. McNerney, J. Chase, C. Burudpakdee, J. H. Lee, C. Jasen, F.
908 Balamuth, D. M. Barrett, B. L. Banwell, K. M. Bernt, A. M. Blatz, K. Chiotos, B. T. Fisher, J. C. Fitzgerald, J.
909 S. Gerber, K. Gollomp, C. Gray, S. A. Grupp, R. M. Harris, T. J. Kilbaugh, A. R. O. John, M. Lambert, E. J.
910 Liebling, M. E. Paessler, W. Petrosa, C. Phillips, A. F. Reilly, N. D. Romberg, A. Seif, D. A. Sesok-Pizzini, K.
911 E. Sullivan, J. Vardaro, E. M. Behrens, D. T. Teachey, H. Bassiri, Multisystem inflammatory syndrome in
912 children and COVID-19 are distinct presentations of SARS-CoV-2. *J. Clin. Invest.* **130**, 5967–5975 (2020).
- 913 18. L. A. Vella, J. R. Giles, A. E. Baxter, D. A. Oldridge, C. Diorio, L. Kuri-Cervantes, C. Alanio, M. B. Pampena,
914 J. E. Wu, Z. Chen, Y. J. Huang, E. M. Anderson, S. Gouma, K. O. McNerney, J. Chase, C. Burudpakdee, J. H.
915 Lee, S. A. Apostolidis, A. C. Huang, D. Mathew, O. Kuthuru, E. C. Goodwin, M. E. Weirick, M. J. Bolton, C.
916 P. Arevalo, A. Ramos, C. J. Jasen, P. E. Conrey, S. Sayed, H. M. Giannini, K. D’Andrea, UPenn COVID
917 Processing Unit, N. J. Meyer, E. M. Behrens, H. Bassiri, S. E. Hensley, S. E. Henrickson, D. T. Teachey, M. R.
918 Betts, E. J. Wherry, Deep immune profiling of MIS-C demonstrates marked but transient immune activation
919 compared to adult and pediatric COVID-19. *Sci Immunol.* **6** (2021), doi:10.1126/sciimmunol.abf7570.
- 920 19. M. J. Carter, M. Fish, A. Jennings, K. J. Doores, P. Wellman, J. Seow, S. Acors, C. Graham, E. Timms, J.
921 Kenny, S. Neil, M. H. Malim, S. M. Tibby, M. Shankar-Hari, Peripheral immunophenotypes in children with
922 multisystem inflammatory syndrome associated with SARS-CoV-2 infection. *Nat. Med.* **26**, 1701–1707 (2020).
- 923 20. R. A. Porritt, A. Binek, L. Paschold, M. N. Rivas, A. McArdle, L. M. Yonker, G. Alter, H. K. Chandnani, M.
924 Lopez, A. Fasano, J. E. Van Eyk, M. Binder, M. Arditi, The autoimmune signature of hyperinflammatory
925 multisystem inflammatory syndrome in children. *J. Clin. Invest.* **131** (2021), doi:10.1172/JCI151520.
- 926 21. C. R. Consiglio, N. Cotugno, F. Sardh, C. Pou, D. Amodio, L. Rodriguez, Z. Tan, S. Zicari, A. Ruggiero, G. R.
927 Pascucci, V. Santilli, T. Campbell, Y. Bryceson, D. Eriksson, J. Wang, A. Marchesi, T. Lakshmikanth, A.
928 Campana, A. Villani, P. Rossi, CACTUS Study Team, N. Landegren, P. Palma, P. Brodin, The Immunology of
929 Multisystem Inflammatory Syndrome in Children with COVID-19. *Cell.* **183**, 968-981.e7 (2020).
- 930 22. C. N. Gruber, R. S. Patel, R. Trachtman, L. Lepow, F. Amanat, F. Krammer, K. M. Wilson, K. Onel, D.
931 Geanon, K. Tuballes, M. Patel, K. Mouskas, T. O’Donnell, E. Merritt, N. W. Simons, V. Barcessat, D. M. Del
932 Valle, S. Udondem, G. Kang, S. Gangadharan, G. Ofori-Amanfo, U. Laserson, A. Rahman, S. Kim-Schulze, A.
933 W. Charney, S. Gnjatich, B. D. Gelb, M. Merad, D. Bogunovic, Mapping Systemic Inflammation and Antibody
934 Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). *Cell.* **183**, 982-995.e14 (2020).
- 935 23. A. Ramaswamy, N. N. Brodsky, T. S. Sumida, M. Comi, H. Asashima, K. B. Hoehn, N. Li, Y. Liu, A. Shah, N.
936 G. Ravindra, J. Bishai, A. Khan, W. Lau, B. Sellers, N. Bansal, P. Guerrierio, A. Unterman, V. Habet, A. J.
937 Rice, J. Catanzaro, H. Chandnani, M. Lopez, N. Kaminski, C. S. Dela Cruz, J. S. Tsang, Z. Wang, X. Yan, S.
938 H. Kleinstein, D. van Dijk, R. W. Pierce, D. A. Hafler, C. L. Lucas, Immune dysregulation and autoreactivity
939 correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children.
940 *Immunity.* **54**, 1083-1095.e7 (2021).
- 941 24. T. V. Lanz, R. C. Brewer, P. P. Ho, J.-S. Moon, K. M. Jude, D. Fernandez, R. A. Fernandes, A. M. Gomez, G.-
942 S. Nadj, C. M. Bartley, R. D. Schubert, I. A. Hawes, S. E. Vazquez, M. Iyer, J. B. Zuchero, B. Teegen, J. E.
943 Dunn, C. B. Lock, L. B. Kipp, V. C. Cotham, B. M. Ueberheide, B. T. Aftab, M. S. Anderson, J. L. DeRisi, M.
944 R. Wilson, R. J. M. Bashford-Rogers, M. Platten, K. C. Garcia, L. Steinman, W. H. Robinson, Clonally
945 expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. *Nature.* **603**, 321–327 (2022).
- 946 25. O. G. Thomas, M. Bronge, K. Tengvall, B. Akpinar, O. B. Nilsson, E. Holmgren, T. Hessa, G. Gafvelin, M.
947 Khademi, L. Alfredsson, R. Martin, A. O. Guerreiro-Cacais, H. Grönlund, T. Olsson, I. Kockum, Cross-
948 reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis. *Sci Adv.* **9**,
949 eadg3032 (2023).
- 950 26. K. Tengvall, J. Huang, C. Hellström, P. Kammer, M. Biström, B. Ayoglu, I. Lima Bomfim, P. Stridh, J. Butt,
951 N. Brenner, A. Michel, K. Lundberg, L. Padyukov, I. E. Lundberg, E. Svenungsson, I. Ernberg, S. Olafsson, A.
952 T. Dilthey, J. Hillert, L. Alfredsson, P. Sundström, P. Nilsson, T. Waterboer, T. Olsson, I. Kockum, Molecular
953 mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.
954 *Proc. Natl. Acad. Sci. U. S. A.* **116**, 16955–16960 (2019).

- 955 27. N. E. Blachère, D. E. Orange, B. D. Santomaso, J. Doerner, P. K. Foo, M. Herre, J. Fak, S. Monette, E. C.
956 Gantman, M. O. Frank, R. B. Darnell, T cells targeting a neuronal paraneoplastic antigen mediate tumor
957 rejection and trigger CNS autoimmunity with humoral activation. *Eur. J. Immunol.* **44**, 3240–3251 (2014).
- 958 28. R. B. Darnell, Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer,
959 immunity, and the brain. *Proc. Natl. Acad. Sci. U. S. A.* **93**, 4529–4536 (1996).
- 960 29. B. O'Donovan, C. Mandel-Brehm, S. E. Vazquez, J. Liu, A. V. Parent, M. S. Anderson, T. Kassimatis, A.
961 Zekeridou, S. L. Hauser, S. J. Pittock, E. Chow, M. R. Wilson, J. L. DeRisi, High-resolution epitope mapping
962 of anti-Hu and anti-Yo autoimmunity by programmable phage display. *Brain Commun.* **2**, fcaa059 (2020).
- 963 30. R. B. Darnell, J. B. Posner, Paraneoplastic syndromes involving the nervous system. *N. Engl. J. Med.* **349**,
964 1543–1554 (2003).
- 965 31. W. K. Roberts, I. J. Deluca, A. Thomas, J. Fak, T. Williams, N. Buckley, A. G. Dousmanis, J. B. Posner, R. B.
966 Darnell, Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells.
967 *J. Clin. Invest.* **119**, 2042–2051 (2009).
- 968 32. W. K. Roberts, R. B. Darnell, Neuroimmunology of the paraneoplastic neurological degenerations. *Curr. Opin.*
969 *Immunol.* **16**, 616–622 (2004).
- 970 33. C. Mandel-Brehm, D. Dubey, T. J. Kryzer, B. D. O'Donovan, B. Tran, S. E. Vazquez, H. A. Sample, K. C.
971 Zorn, L. M. Khan, I. O. Bledsoe, A. McKeon, S. J. Pleasure, V. A. Lennon, J. L. DeRisi, M. R. Wilson, S. J.
972 Pittock, Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis. *N. Engl. J.*
973 *Med.* **381**, 47–54 (2019).
- 974 34. A. Venkatraman, P. Opal, Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. *Ann Clin*
975 *Transl Neurol.* **3**, 655–663 (2016).
- 976 35. J. Pfeifer, B. Thurner, C. Kessel, N. Fadle, P. Kheiroddin, E. Regitz, M.-C. Hoffmann, I. A. Kos, K.-D. Preuss,
977 Y. Fischer, K. Roemer, S. Lohse, K. Heyne, M.-C. Detemple, M. Fedlmeier, H. Juenger, H. Sauer, S. Meyer, T.
978 Rohrer, H. Wittkowski, S. L. Becker, K. Masjosthusmann, R. Bals, S. Gerling, S. Smola, M. Bewarder, E. Birk,
979 A. Keren, M. Böhm, A. Jakob, H. Abdul-Khaliq, J. Anton, M. Kabesch, R. M. Pino-Ramirez, D. Foell, L.
980 Thurner, Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in
981 children: a multicentre, retrospective, cohort study. *Lancet Rheumatol.* **4**, e329–e337 (2022).
- 982 36. R. A. Porritt, L. Paschold, M. N. Rivas, M. H. Cheng, L. M. Yonker, H. Chandnani, M. Lopez, D. Simnica, C.
983 Schultheiß, C. Santiskulvong, J. Van Eyk, J. K. McCormick, A. Fasano, I. Bahar, M. Binder, M. Arditì, HLA
984 class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children. *J. Clin.*
985 *Invest.* **131** (2021), doi:10.1172/JCI146614.
- 986 37. K. Sacco, R. Castagnoli, S. Vakkilainen, C. Liu, O. M. Delmonte, C. Oguz, I. M. Kaplan, S. Alehashemi, P. D.
987 Burbelo, F. Bhuyan, A. A. de Jesus, K. Dobbs, L. B. Rosen, A. Cheng, E. Shaw, M. S. Vakkilainen, F. Pala, J.
988 Lack, Y. Zhang, D. L. Fink, V. Oikonomou, A. L. Snow, C. L. Dalgard, J. Chen, B. A. Sellers, G. A.
989 Montealegre Sanchez, K. Barron, E. Rey-Jurado, C. Vial, M. C. Poli, A. Licari, D. Montagna, G. L. Marseglia,
990 F. Licciardi, U. Ramenghi, V. Discepolo, A. Lo Vecchio, A. Guarino, E. M. Eisenstein, L. Imberti, A. Sottini,
991 A. Biondi, S. Mató, D. Gerstbacher, M. Truong, M. A. Stack, M. Magliocco, M. Bosticardo, T. Kawai, J. J.
992 Danielson, T. Hulett, M. Askenazi, S. Hu, NIAID Immune Response to COVID Group, Chile MIS-C Group,
993 Pavia Pediatric COVID-19 Group, J. I. Cohen, H. C. Su, D. B. Kuhns, M. S. Lionakis, T. M. Snyder, S. M.
994 Holland, R. Goldbach-Mansky, J. S. Tsang, L. D. Notarangelo, Immunopathological signatures in multisystem
995 inflammatory syndrome in children and pediatric COVID-19. *Nat. Med.* **28**, 1050–1062 (2022).
- 996 38. M. Moreews, K. Le Gouge, S. Khaldi-Plassart, R. Pescarmona, A.-L. Mathieu, C. Malcus, S. Djebali, A.
997 Bellomo, O. Dauwalder, M. Perret, M. Villard, E. Chopin, I. Rouvet, F. Vandenesch, C. Dupieux, R. Pouyau, S.
998 Teyssedre, M. Guerder, T. Louazon, A. Moulin-Zinsch, M. Duperril, H. Patural, L. Giovannini-Chami, A.
999 Portefaix, B. Kassai, F. Venet, G. Monneret, C. Lombard, H. Flodrops, J.-M. De Guillebon, F. Bajolle, V.
1000 Launay, P. Bastard, S.-Y. Zhang, V. Dubois, O. Thauinat, J.-C. Richard, M. Mezidi, O. Allatif, K. Saker, M.

- 1001 Dreux, L. Abel, J.-L. Casanova, J. Marvel, S. Trouillet-Assant, D. Klatzmann, T. Walzer, E. Mariotti-
1002 Ferrandiz, E. Javouhey, A. Belot, Polyclonal expansion of TCR Vbeta 21.3+ CD4+ and CD8+ T cells is a
1003 hallmark of Multisystem Inflammatory Syndrome in Children. *Sci Immunol.* **6** (2021),
1004 doi:10.1126/sciimmunol.abh1516.
- 1005 39. L. Hoste, L. Roels, L. Naesens, V. Bosteels, S. Vanhee, S. Dupont, C. Bosteels, R. Browaeys, N. Vandamme,
1006 K. Verstaen, J. Roels, K. F. A. Van Damme, B. Maes, E. De Leeuw, J. Declercq, H. Aegerter, L. Seys, U.
1007 Smole, S. De Prijck, M. Vanheerswynghels, K. Claes, V. Debacker, G. Van Isterdael, L. Backers, K. B. M.
1008 Claes, P. Bastard, E. Jouanguy, S.-Y. Zhang, G. Mets, J. Dehoorne, K. Vandekerckhove, P. Schelstraete, J.
1009 Willems, MIS-C Clinicians, P. Stordeur, S. Janssens, R. Beyaert, Y. Saeys, J.-L. Casanova, B. N. Lambrecht,
1010 F. Haerynck, S. J. Tavernier, TIM3+ TRBV11-2 T cells and IFN γ signature in patrolling monocytes and
1011 CD16+ NK cells delineate MIS-C. *J. Exp. Med.* **219** (2022), doi:10.1084/jem.20211381.
- 1012 40. K. Rybkina, J. N. Bell, M. C. Bradley, T. Wohlbold, M. Scafuro, W. Meng, R. C. Korenberg, J. Davis-Porada,
1013 B. R. Anderson, R. J. Weller, J. D. Milner, A. Moscona, M. Porotto, E. T. Luning Prak, K. Pethe, T. J.
1014 Connors, D. L. Farber, SARS-CoV-2 infection and recovery in children: Distinct T cell responses in MIS-C
1015 compared to COVID-19. *J. Exp. Med.* **220** (2023), doi:10.1084/jem.20221518.
- 1016 41. D. Lee, J. Le Pen, A. Yatim, B. Dong, Y. Aquino, M. Ogishi, R. Pescarmona, E. Talouarn, D. Rinchai, P.
1017 Zhang, M. Perret, Z. Liu, I. Jordan, S. Elmas Bozdemir, G. I. Bayhan, C. Beaufils, L. Bizien, A. Bisiaux, W.
1018 Lei, M. Hasan, J. Chen, C. Gaughan, A. Asthana, V. Libri, J. M. Luna, F. Jaffré, H.-H. Hoffmann, E.
1019 Michailidis, M. Moreews, Y. Seeleuthner, K. Bilguvar, S. Mane, C. Flores, Y. Zhang, A. A. Arias, R. Bailey,
1020 A. Schlüter, B. Milisavljevic, B. Bigio, T. Le Voyer, M. Materna, A. Gervais, M. Moncada-Velez, F. Pala, T.
1021 Lazarov, R. Levy, A.-L. Neehus, J. Rosain, J. Peel, Y.-H. Chan, M.-P. Morin, R. M. Pino-Ramirez, S. Belkaya,
1022 L. Lorenzo, J. Anton, S. Delafontaine, J. Toubiana, F. Bajolle, V. Fumadó, M. L. DeDiego, N. Fidouh, F.
1023 Rozenberg, J. Pérez-Tur, S. Chen, T. Evans, F. Geissmann, P. Lebon, S. R. Weiss, D. Bonnet, X. Duval, CoV-
1024 Contact Cohort \S , H. G. E. Covid, Q. Pan-Hammarström, A. M. Planas, I. Meyts, F. Haerynck, A. Pujol, V.
1025 Sancho-Shimizu, C. Dalgard, J. Bustamante, A. Puel, S. Boisson-Dupuis, B. Boisson, T. Maniatis, Q. Zhang, P.
1026 Bastard, L. Notarangelo, V. Béziat, R. Perez de Diego, C. Rodriguez-Gallego, H. C. Su, R. P. Lifton, E.
1027 Jouanguy, A. Cobat, L. Alsina, S. Keles, E. Haddad, L. Abel, A. Belot, L. Quintana-Murci, C. M. Rice, R. H.
1028 Silverman, S.-Y. Zhang, J.-L. Casanova, Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem
1029 inflammatory syndrome in children. *Science*, eabo3627 (2022).
- 1030 42. W. Guo, J. Wei, X. Zhong, R. Zang, H. Lian, M.-M. Hu, S. Li, H.-B. Shu, Q. Yang, SNX8 modulates the
1031 innate immune response to RNA viruses by regulating the aggregation of VISA. *Cell. Mol. Immunol.* **17**, 1126–
1032 1135 (2020).
- 1033 43. H. B. Larman, Z. Zhao, U. Laserson, M. Z. Li, A. Ciccia, M. A. M. Gakidis, G. M. Church, S. Kesari, E. M.
1034 Leproust, N. L. Solimini, S. J. Elledge, Autoantigen discovery with a synthetic human peptidome. *Nat.*
1035 *Biotechnol.* **29**, 535–541 (2011).
- 1036 44. S. E. Vazquez, S. A. Mann, A. Bodansky, A. F. Kung, Z. Quandt, E. M. N. Ferré, N. Landegren, D. Eriksson,
1037 P. Bastard, S.-Y. Zhang, J. Liu, A. Mitchell, I. Proekt, D. Yu, C. Mandel-Brehm, C.-Y. Wang, B. Miao, G.
1038 Sowa, K. Zorn, A. Y. Chan, V. M. Tagi, C. Shimizu, A. Tremoulet, K. Lynch, M. R. Wilson, O. Kämpe, K.
1039 Dobbs, O. M. Delmonte, R. Bacchetta, L. D. Notarangelo, J. C. Burns, J.-L. Casanova, M. S. Lionakis, T. R.
1040 Torgerson, M. S. Anderson, J. L. DeRisi, Autoantibody discovery across monogenic, acquired, and COVID-19-
1041 associated autoimmunity with scalable PhIP-seq. *Elife.* **11** (2022), doi:10.7554/eLife.78550.
- 1042 45. S. E. Vazquez, E. M. Ferré, D. W. Scheel, S. Sunshine, B. Miao, C. Mandel-Brehm, Z. Quandt, A. Y. Chan, M.
1043 Cheng, M. German, M. Lionakis, J. L. DeRisi, M. S. Anderson, Identification of novel, clinically correlated
1044 autoantigens in the monogenic autoimmune syndrome APS1 by proteome-wide PhIP-Seq. *Elife.* **9** (2020),
1045 doi:10.7554/eLife.55053.
- 1046 46. C. Mandel-Brehm, S. E. Vazquez, C. Liverman, M. Cheng, Z. Quandt, A. F. Kung, A. Parent, B. Miao, E.
1047 Disse, C. Cugnet-Anceau, S. Dalle, E. Orlova, E. Frolova, D. Alba, A. Michels, B. E. Oftedal, M. S. Lionakis,
1048 E. S. Husebye, A. K. Agarwal, X. Li, C. Zhu, Q. Li, E. Oral, R. Brown, M. S. Anderson, A. Garg, J. L. DeRisi,

- 1049 Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy. *Diabetes*. **72**, 59–70
1050 (2023).
- 1051 47. P. D. Burbelo, R. Castagnoli, C. Shimizu, O. M. Delmonte, K. Dobbs, V. Discepolo, A. Lo Vecchio, A.
1052 Guarino, F. Licciardi, U. Ramenghi, E. Rey-Jurado, C. Vial, G. L. Marseglia, A. Licari, D. Montagna, C. Rossi,
1053 G. A. Montealegre Sanchez, K. Barron, B. M. Warner, J. A. Chiorini, Y. Espinosa, L. Noguera, L. Dropulic, M.
1054 Truong, D. Gerstbacher, S. Mató, J. Kanegaye, A. H. Tremoulet, Pediatric Emergency Medicine Kawasaki
1055 Group, E. M. Eisenstein, H. C. Su, L. Imberti, M. C. Poli, J. C. Burns, L. D. Notarangelo, J. I. Cohen,
1056 Autoantibodies Against Proteins Previously Associated With Autoimmunity in Adult and Pediatric Patients
1057 With COVID-19 and Children With MIS-C. *Front. Immunol.* **13**, 841126 (2022).
- 1058 48. L. Johannes, C. Wunder, The SNXy flavours of endosomal sorting. *Nat. Cell Biol.* **13** (2011), pp. 884–886.
- 1059 49. J. Wei, H. Lian, W. Guo, Y.-D. Chen, X.-N. Zhang, R. Zang, L. Zhong, Q. Yang, M.-M. Hu, W.-W. Luo, H.-B.
1060 Shu, S. Li, SNX8 modulates innate immune response to DNA virus by mediating trafficking and activation of
1061 MITA. *PLoS Pathog.* **14**, e1007336 (2018).
- 1062 50. J. Wei, W. Guo, H. Lian, Q. Yang, H. Lin, S. Li, H.-B. Shu, SNX8 mediates IFN γ -triggered noncanonical
1063 signaling pathway and host defense against *Listeria monocytogenes*. *Proc. Natl. Acad. Sci. U. S. A.* **114**,
1064 13000–13005 (2017).
- 1065 51. C. R. Zamecnik, J. V. Rajan, K. A. Yamauchi, S. A. Mann, R. P. Loudermilk, G. M. Sowa, K. C. Zorn, B. D.
1066 Alvarenga, C. Gaebler, M. Caskey, M. Stone, P. J. Norris, W. Gu, C. Y. Chiu, D. Ng, J. R. Byrnes, X. X. Zhou,
1067 J. A. Wells, D. F. Robbiani, M. C. Nussenzweig, J. L. DeRisi, M. R. Wilson, ReScan, a Multiplex Diagnostic
1068 Pipeline, Pans Human Sera for SARS-CoV-2 Antigens. *Cell Rep Med.* **1**, 100123 (2020).
- 1069 52. A. Pugliese, Autoreactive T cells in type 1 diabetes. *J. Clin. Invest.* **127**, 2881–2891 (2017).
- 1070 53. J. M. Dan, C. S. Lindestam Arlehamn, D. Weiskopf, R. da Silva Antunes, C. Havenar-Daughton, S. M. Reiss,
1071 M. Brigger, M. Bothwell, A. Sette, S. Crotty, A Cytokine-Independent Approach To Identify Antigen-Specific
1072 Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood. *J.*
1073 *Immunol.* **197**, 983–993 (2016).
- 1074 54. C. Havenar-Daughton, S. M. Reiss, D. G. Carnathan, J. E. Wu, K. Kendric, A. Torrents de la Peña, S. P.
1075 Kasturi, J. M. Dan, M. Bothwell, R. W. Sanders, B. Pulendran, G. Silvestri, S. Crotty, Cytokine-Independent
1076 Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates
1077 Using a Live Cell Activation-Induced Marker Technique. *J. Immunol.* **197**, 994–1002 (2016).
- 1078 55. C. Rydzynski Moderbacher, S. I. Ramirez, J. M. Dan, A. Grifoni, K. M. Hastie, D. Weiskopf, S. Belanger, R.
1079 K. Abbott, C. Kim, J. Choi, Y. Kato, E. G. Crotty, C. Kim, S. A. Rawlings, J. Mateus, L. P. V. Tse, A. Frazier,
1080 R. Baric, B. Peters, J. Greenbaum, E. Ollmann Saphire, D. M. Smith, A. Sette, S. Crotty, Antigen-Specific
1081 Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.
1082 *Cell.* **183**, 996-1012.e19 (2020).
- 1083 56. R. Vita, S. Mahajan, J. A. Overton, S. K. Dhanda, S. Martini, J. R. Cantrell, D. K. Wheeler, A. Sette, B. Peters,
1084 The Immune Epitope Database (IEDB): 2018 update. *Nucleic Acids Res.* **47**, D339–D343 (2019).
- 1085 57. J. S. Lee, S. Park, H. W. Jeong, J. Y. Ahn, S. J. Choi, H. Lee, B. Choi, S. K. Nam, M. Sa, J.-S. Kwon, S. J.
1086 Jeong, H. K. Lee, S. H. Park, S.-H. Park, J. Y. Choi, S.-H. Kim, I. Jung, E.-C. Shin, Immunophenotyping of
1087 COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. *Sci*
1088 *Immunol.* **5** (2020), doi:10.1126/sciimmunol.abd1554.
- 1089 58. C. de Cevins, M. Luka, N. Smith, S. Meynier, A. Magérus, F. Carbone, V. García-Paredes, L. Barnabei, M.
1090 Batignes, A. Boullé, M.-C. Stolzenberg, B. P. Pérot, B. Charbit, T. Fali, V. Pirabakaran, B. Sorin, Q. Riller, G.
1091 Abdessalem, M. Beretta, L. Grzelak, P. Goncalves, J. P. Di Santo, H. Mouquet, O. Schwartz, M. Zarhrate, M.
1092 Parisot, C. Bole-Feysot, C. Masson, N. Cagnard, A. Corneau, C. Brunaud, S.-Y. Zhang, J.-L. Casanova, B.
1093 Bader-Meunier, J. Haroche, I. Melki, M. Lorrot, M. Oualha, F. Moulin, D. Bonnet, Z. Belhadjer, M. Leruez, S.

- 1094 Allali, C. Gras-Leguen, L. de Pontual, Pediatric-Biocovid Study Group, A. Fischer, D. Duffy, F. Rieux-Laucat,
1095 J. Toubiana, M. M. Ménager, A monocytic/dendritic cell molecular signature of SARS-CoV-2-related
1096 multisystem inflammatory syndrome in children with severe myocarditis. *Med.* **2**, 1072-1092.e7 (2021).
- 1097 59. M. Miron, W. Meng, A. M. Rosenfeld, S. Dvorkin, M. M. L. Poon, N. Lam, B. V. Kumar, Y. Louzoun, E. T.
1098 Luning Prak, D. L. Farber, Maintenance of the human memory T cell repertoire by subset and tissue site.
1099 *Genome Med.* **13**, 100 (2021).
- 1100 60. HAN Archive - 00432 (2021), (available at <https://emergency.cdc.gov/han/2020/han00432.asp>).
- 1101 61. E. Rackaityte, I. Proekt, H. S. Miller, A. Ramesh, J. F. Brooks, A. F. Kung, C. Mandel-Brehm, D. Yu, C.
1102 Zamecnik, R. Bair, S. E. Vazquez, S. Sunshine, C. L. Abram, C. A. Lowell, G. Rizzuto, M. R. Wilson, J.
1103 Zikherman, M. S. Anderson, J. L. DeRisi, Validation of a murine proteome-wide phage display library for the
1104 identification of autoantibody specificities. *bioRxiv* (2023), p. 2023.04.07.535899, ,
1105 doi:10.1101/2023.04.07.535899.
- 1106 62. J. J. Sabatino Jr, K. Mittl, W. M. Rowles, K. McPolin, J. V. Rajan, M. T. Laurie, C. R. Zamecnik, R. Dandekar,
1107 B. D. Alvarenga, R. P. Loudermilk, C. Gerungan, C. M. Spencer, S. A. Sagan, D. G. Augusto, J. R. Alexander,
1108 J. L. DeRisi, J. A. Hollenbach, M. R. Wilson, S. S. Zamvil, R. Bove, Multiple sclerosis therapies differentially
1109 affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function. *JCI Insight.* **7** (2022),
1110 doi:10.1172/jci.insight.156978.
- 1111 63. J. J. Sabatino Jr, M. R. Wilson, P. A. Calabresi, S. L. Hauser, J. P. Schneck, S. S. Zamvil, Anti-CD20 therapy
1112 depletes activated myelin-specific CD8+ T cells in multiple sclerosis. *Proc. Natl. Acad. Sci. U. S. A.* **116**,
1113 25800–25807 (2019).
- 1114 64. F. A. Wolf, P. Angerer, F. J. Theis, SCANPY: large-scale single-cell gene expression data analysis. *Genome*
1115 *Biol.* **19**, 15 (2018).
- 1116 65. A. Butler, P. Hoffman, P. Smibert, E. Papalexi, R. Satija, Integrating single-cell transcriptomic data across
1117 different conditions, technologies, and species. *Nat. Biotechnol.* **36**, 411–420 (2018).
- 1118 66. K. Polański, M. D. Young, Z. Miao, K. B. Meyer, S. A. Teichmann, J.-E. Park, BBKNN: fast batch alignment
1119 of single cell transcriptomes. *Bioinformatics.* **36**, 964–965 (2020).
- 1120 67. V. A. Traag, L. Waltman, N. J. van Eck, From Louvain to Leiden: guaranteeing well-connected communities.
1121 *Sci. Rep.* **9**, 5233 (2019).
- 1122 68. E. Becht, L. McInnes, J. Healy, C.-A. Dutertre, I. W. H. Kwok, L. G. Ng, F. Ginhoux, E. W. Newell,
1123 Dimensionality reduction for visualizing single-cell data using UMAP. *Nat. Biotechnol.* (2018),
1124 doi:10.1038/nbt.4314.
- 1125 69. F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer, R.
1126 Weiss, V. Dubourg, J. Vanderplas, A. Passos, D. Cournapeau, M. Brucher, M. Perrot, É. Duchesnay, Scikit-
1127 learn: Machine Learning in Python. *J. Mach. Learn. Res.* **12**, 2825–2830 (2011).



c PhIP-Seq Logistic Regression: MIS-C vs Controls








Figure 1: Autoantigens distinguish MIS-C from at-risk controls.

(a) Design of PhIP-Seq experiment comparing MIS-C patients (n=199) and at-risk controls (n=45; children with SARS-CoV-2 infection at least 5 weeks prior to sample collection without symptoms of MIS-C). **(b)** Venn-diagram highlighting the number of autoantigens identified with statistically significant PhIP-Seq enrichment (*'Enrichment set'*: Gray circle; p-value <0.01 on Kolmogorov-Smirnov (KS) test with Bonferroni FDR correction) and autoantigens identified which contribute to a logistic regression classifier of MIS-C relative to at-risk controls (*'Classifier set'*: Purple circle). There are 35 autoantigens present in both the *classifier set* and *enrichment set* (Red; union of Venn Diagram) of which 30 are exclusive to MIS-C and referred to as the *'MIS-C Set'* (no two controls have low reactivity as defined by fold change signal over mean of Protein A/G beads only (FC > mock-IP) of 3 or greater, and no single control has high reactivity defined as FC > mock-IP greater than 10). **(c)** Receiver operating characteristic curve for the logistic regression classifier and barplot showing autoantigens with the top 10 logistic regression coefficients. **(d)** Hierarchically clustered (Pearson) heatmap showing the PhIP-Seq enrichment (FC > mock-IP) for the 30 autoantigens in the *MIS-C Set* in each MIS-C patient and each at-risk plasma control. **(e)** Radioligand binding assay (RLBA) values for 196 of the 199 individuals with MIS-C and each at-risk control for each of the top 3 autoantibodies identified by PhIP-Seq logistic regression. **(f)** Logistic regression receiver operating characteristic curve using input RLBA values to distinguish MIS-C from at-risk controls. For the figure, Mann-Whitney U testing was performed; *****p-value < 0.00001.

a



b





Figure 2: Autoantibodies in MIS-C patients target a single epitope within SNX8.


(a) PhIP-Seq signal (reads per 100k) for each MIS-C patient (n=199) and each at-risk control (n=45) across each of the 19 bacteriophage encoded peptide fragments which together tile the full length SNX8 protein. (b) SLBA enrichments (normalized antibody indices) for each sequential alanine mutagenesis construct. Constructs were designed with 10 amino-acid alanine windows shifted by 5 amino-acids until the entire immunodominant SNX8 region (SNX8 Fragment 2) was scanned. Values are averages of 6 separate MIS-C patients. Identified autoantibody epitope bounded by vertical gray dotted lines.

a

Favors MIS-C




b



c

d



e



Figure 3: MIS-C patient antibodies preferentially target distinct region of SARS-CoV-2 N protein.

(a) Relative PhIP-Seq signal (fold-change over mean of 48 pre-COVID controls (FC > Pre-COVID)) in MIS-C patients (n=181) and at-risk controls (n=45) using custom phage display library expressing entire SARS-CoV-2 proteome to different regions of SARS-CoV-2. Only regions with mean antibody signal >1.5 fold above pre-COVID controls shown. Antigenicity (sum of mean FC > pre-COVID in MIS-C and at-risk controls) represented by darker shades. Length of bars represents statistical difference in signal between MIS-C and at-risk controls to a particular region (-log₁₀ of Kolmogorov-Smirnov test p-values), with upward deflections representing enrichment in MIS-C versus at-risk controls, and downward deflections representing less signal in MIS-C. (b) Barplots showing PhIP-Seq signal (FC > Pre-COVID) across the specific region of the SARS-CoV-2 N protein with most divergent response in MIS-C samples relative to at-risk controls. Amino acid sequence of region with highest relative enrichment in MIS-C highlighted in green, and referred to as the MIS-C associated domain of SARS-CoV-2 (MADS). (c) Stripplots showing MADS SLBA enrichments (normalized antibody indices) in MIS-C patients (n=11) relative to at-risk controls (n=5). (d) SLBA signal (normalized antibody indices) for full sequential alanine mutagenesis scans within the same 3 individuals for SNX8 (left) and MADS (right) identification of epitopes to each (bounded by red dotted vertical lines). (e) Multiple sequence alignment of SNX8 and MADS epitopes (ClustalOmega; asterisk=identical amino acid; colon=strongly similar properties with Gonnet PAM 250 matrix score >0.5) with amino acid sequence for similarity region shown (orange). For the figure, Kolmogorov-Smirnov testing was used to compare PhIP-Seq signal, and Mann-Whitney U testing was used to compare SLBA signal; ns p-value > 0.05, **p-value <0.01, ****p-value < 0.00001.






Figure 4: MIS-C patients harbor T-cells autoreactive to SNX8 which cross-react with SARS-CoV-2.

(a) Representative activation induced marker (AIM) assay flow cytometry gating strategy measuring percent of CD4+ T-cells which activate in response to SNX8 protein (CD137+/OX40+) and percent of CD8+ T-cells which activate (CD137+/CD69+). (b) Barplot showing distribution of T-cells which activate in response to either vehicle (culture media + 0.2% DMSO) or SNX8 peptide pool (SNX8 peptide + culture media + 0.2% DMSO). (c) Gating strategy used to identify CD8+ T-cells which bound to SNX8 epitope and/or MADS N protein epitope (CD8+ T-cells positive for PE). Representative MIS-C patient and control showing each CD8+ T-cell which bound to any tetramer (PE+) and the relative binding of that T-cell to both the SNX8 epitope (BV421+) and the MADS N protein epitope (APC+) identifying cross-reactive T-cells (PE+/APC+/BV421+). (d) Barplot showing percentage of CD8+ T-cells which are cross-reactive to both SNX8 and MADS in MIS-C and controls (3 MIS-C patients and 3 at-risk controls). For the figure, Mann-Whitney U testing was performed; ***p-value <0.001.




Supplemental Figure 1: Previously reported MIS-C associated autoantigens.

(a) Heatmap showing distribution of PhIP-Seq enrichments (FC > Mock-IP) of previously reported MIS-C autoantibodies in MIS-C patients (n=199) and at-risk controls (n=45). **(b)** Stripplots showing distribution of signal (normalized antibody index) for antibodies targeting IL-1 receptor antagonist (IL-1Ra) measured by RLBA in at-risk controls (blue; n=45), MIS-C patient samples containing IVIG (red; n=135), and MIS-C patient samples without IVIG (green; n=61). Dotted line at 3 standard deviations above the mean of controls. For the figure, Mann-Whitney U testing was performed; ns p-value > 0.05, ****p-value < 0.0001, *****p-value < 0.00001.



Supplemental Figure 2: Absence of tissue specific autoantibodies correlating to phenotypes.


Heatmap of p-values (Kolmogorov-Smirnov testing) for differences in autoantibody enrichment for MIS-C patients with versus without each clinical phenotype. Significant p-values in the negative direction (in which there is increased signal in individuals without the phenotype) are masked (colored as $p > 0.05$). For each autoantigen, tissue RNA-sequencing data from Human Protein Atlas (Proteinatlas.org) is shown. Amount of expression in cardiac tissue in top row (Very high= $nTPM > 1000$, High= $nTPM 100-1000$, Moderate= $nTPM 10-100$, Low= $nTPM < 10$), and predominant tissue type in second-from-top row. Explanations of criteria for MIS-C phenotypes, and distribution of each phenotype within the cohort, can be found in Supplemental Table 1.




Supplemental Figure 3: Significantly increased autoantibodies is MIS-C samples without IVIG.

(a) Striplots showing RLBA enrichments (normalized antibody indices) in samples containing IVIG (green) and samples without IVIG (magenta) for ERFL, SNX8, and KDELRL1 in MIS-C patients (n=196) and at-risk controls (n=45). (b) Striplots showing RLBA enrichment only in those MIS-C samples without IVIG (n=62) relative to at-risk controls (n=45). For the figure, Mann-Whitney U testing was performed; ***p-value < 0.001, ****p-value < 0.0001, *****p-value < 0.00001.

a




b




Supplemental Figure 4: Validation of autoantibody classifier using independent MIS-C cohort.

(a) Striplots showing RLBA enrichments (normalized antibody indices) for ERFL, SNX8, and KDELRL1 in an independent cohort of children with MIS-C (red; n=24) compared to children severely ill with acute COVID-19 (yellow; n=29) and at-risk controls (blue; n=45) (b) Logistic regression receiver operating characteristic curves for classification of the independent MIS-C cohort versus at-risk controls (left) and the independent MIS-C cohort versus children severely ill with acute COVID-19 (right). For the figure, Mann-Whitney U testing was performed; ns p-value > 0.05, *p-value < 0.05, ** p-value < 0.01, ***p-value < 0.001, ****p-value < 0.0001.




Supplemental Figure 5: Prevalence of epitope specific SNX8 autoantibodies in MIS-C and controls.

Paired stripplots showing SLBA enrichments (normalized antibody indices) in MIS-C patients (n=182) and at-risk controls (n=45) for the full 49 amino acid SNX8 wild-type (WT) polypeptide fragment (lavender) relative to the same SNX8 fragment with alanine mutagenesis of the [PSRMQMPQG] epitope (white). SNX8 WT fragment SLBA values are the means of technical replicates, SNX8 epitope mutagenesis values are from a single experiment. For the figure, Mann-Whitney U testing was performed; ns p-value > 0.05, ****p-value < 0.0001.



Supplemental Figure 6: Activation of CD4+ and CD8+ T-cells with associated HLA type.


Stripplots showing distribution of CD4+, CD8+, and total T-cells which activate in response to either vehicle (culture media + 0.2% DMSO) or SNX8 peptide pool (SNX8 peptide + culture media + 0.2% DMSO) using AIM assay. HLA type indicated by color of dot. HLA unpredicted means patient contained none of the MIS-C associated HLA types. Dotted line at 3 standard deviations above the mean of the SNX8 stimulated controls. For the figure, Mann-Whitney U testing was performed; ***p-value <0.001.




Supplemental Figure 7: HLA-A*02 preferentially displays MADS and SNX8 similarity regions on MHC1.

(a) Computationally predicted MHC1 presentation scores (Immune Epitope Database; IEDB.org) for each possible peptide fragment of full length SARS-CoV-2 N protein for each of the three MIS-C associated HLA types (A*02, B*35 and C*04) relative to a reference set of HLA-types encompassing over 99% of humans. Those fragments containing the MADS similarity region “LQLPQG” in orange. Percent of fragments within each specific HLA subtype with a score greater than 0.1 (likely to be presented) shown on right. **(b)** Identical analysis but using full length SNX8 protein rather than SARS-CoV-2 NP, and the SNX8 similarity region “MGMPQG” rather than the MADS region “LQLPQG”. For the figure, the peptide MHC1 presentation scores for all peptides within an HLA type were normally distributed, so a t-test was used to compare signal. ns p-value > 0.05, ***p-value < 0.001, ****p-value < 0.0001.

T-cell Activation to SNX8 Epitope




Supplemental Figure 8: Stimulation with SNX8 epitope only is sufficient to activate T-cells in MIS-C patients. Stripplots showing percentage of total T-cells which activate in response to either vehicle (culture media + 0.2% DMSO) or the SNX8 Epitope (SNX8 Epitope (Materials) + culture media + 0.2% DMSO) in MIS-C patients (n=2) and at-risk controls (n=4) measured by AIM assay. Dotted line at 3 standard deviations above mean of SNX8 Epitope stimulated controls.



Supplemental Figure 9: SNX8 expression during viral infection.

(a) UMAPs showing SNX8 expression in various peripheral blood cell types during SARS-CoV-2 infection. (b) Mean expression and percent of cells expressing SNX8 in peripheral blood subsets during SARS-CoV-2 infection. (c) Mean expression and percent of cells expressing SNX8 averaged across all peripheral blood mononuclear cells from SARS-CoV-2 infected individuals without symptoms, with mild symptoms, or with severe disease compared to uninfected controls. (d) Mean expression and percent of cells expressing SNX8, OAS1, OAS2, and MAVS in peripheral blood subsets during SARS-CoV-2 infection. (e) Relative expression of SNX8, OAS1, OAS2, and MAVS during influenza infection compared to different severities of SARS-CoV-2 infection.



Supplemental Figure 10: Representative flow cytometry for AIM, tetramer, and serotyping experiments.

(a) FlowJo plots showing gating strategy for identifying CD4 positive and CD8 positive T-cells for the AIM analysis shown in Figure 4. (b) FlowJo gating strategy for the tetramer assay showing isolation of PE-tetramer positive CD8 positive T-cells. (c) FlowJo plots showing results of serotyping for the PBMCs used in the SNX8/MADS tetramer cross-reactivity assay which did not have sufficient cells for genotyping. Shown is the 1 MIS-C patient (far left) and 3 controls (middle 3) which are positive for HLA-A*02 and were used in the tetramer cross-reactivity assay, and one control negative for HLA-A*02 (far right) which was not used.